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_____________________________________________________________Abstract 
The Blood Retinal Barrier is composed of an inner BRB (iBRB) and outer BRB (oBRB). The 
iBRB is formed by retinal microvascular endothelial cells. The oBRB is formed by a 
monolayer of Retinal Pigment Epithelial (RPE) cells which lines and supports the functions of 
the photoreceptor layer. The tight junctions in the oBRB regulate ion and macromolecular 
transport along the paracellular layer. Neovascular Age Related Macular Degeneration 
(ARMD) is associated with alterations of the oBRB. Vascular Endothelial Growth Factor 
(VEGF) levels are high in neovascular ARMD and may promote oBRB breakdown. Low 
grade inflammation also plays a role in ARMD with infiltration of the BRB by macrophages 
and lymphocytes. Inflammation induced accumulation of macrophages, followed by secretion 
of pro-inflammatory cytokines Tumour necrosis factor – α (TNF- α) or Interleukin-1β (IL-
1β), may affect oBRB function.  
The aim of this thesis was to investigate the effect of the VEGF family of growth factors and 
cytokines TNF- α and IL-1β on oBRB function. The human RPE line ARPE-19 was 
employed as an in vitro model of the oBRB. Two-Dimensional gel electrophoresis was 
employed to study the effect of growth factors on the RPE proteome. The barrier properties of 
the oBRB were evaluated by expression of the TJ proteins occludin or Zo-1, or claudins-1, 2, 
3 and 4, determined by western blotting analysis. Claudins 2, 3 and 4 were found to be 
significantly up-regulated by TNF-α, while interleukin 1 β-treated RPE showed increased 
expression of Claudins 1 and 3. 
Immunoflourescence imaging showed junctional loss of occludin and ZO-1 in VEGF, TNF-α 
and IL-1β treated RPE. Placental growth factor (PlGF), a member of the VEGF family, has 
been found to be produced by hypoxia-stimulated RPE, and treatment with PlGF was shown 
to cause a disruption of junctional integrity of occludin in RPE. Cytokine induced regulation 
of Zo-1, occludin and claudins may lead to oBRB breakdown in ARMD, affecting 
photoreceptor function and leading to vision loss.  
These findings will help in identifying inflammatory mediators important in the pathogenesis 
of ARMD, and molecular targets for control of ARMD related inflammation and disease 
progression. 
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The Blood Retinal barrier (BRB) located in the eye provides a selective barrier for regulation 
of the retinal milieu and for maintaining the specialised environment of the neural retina. The 
concept of a retinal barrier impermeable to dyes, with possible structural similarity to the 
Blood Brain Barrier (BBB), was proposed as early as 1913 by Schnaudigal (Cunha-Vaz et al 
1966, Schnaudigal O.V 1913). Unlike BBB, the BRB is comprised of two layers – inner and 
outer. The inner layer (iBRB) is composed of the Retinal Microvascular Endothelial cells 
(RMECs) and the outer layer (oBRB) comprises the Retinal Pigment Epithelial (RPE) cells. 
Together, the BRB layers regulate the passage of ions, water and protein in and out of the 
retina, in response to the varying metabolic demands of the retina (Cunha-Vaz et al., 2010). 
The barrier property of the BRB is due to the presence of ‘tight junctions’ (TJs) which seal 
the paracellular space from the outer environment. The TJs are formed by interaction between 
membrane proteins in the adjacent cells in the BRB. 
 
The oBRB regulates permeability of molecules from choroid into the retinal 
microenvironment. RMEC and RPE cells secrete cytokines, growth factors and other key 
molecules essential for maintenance of retinal homeostasis (Holtkamp et al. 1999). The 
integrity of the BRB is critical to normal visual function (Gardner et al, 1999). Abnormal 
permeability change or breakdown of BRB is the hallmark of several pathological conditions 
that affect the neural retina.  
 
1.1. Inner Blood Retinal Barrier 
The iBRB is structurally similar to the Blood Brain Barrier (BBB) with the RMECs 
surrounded by retinal pericytes and macroglial cells (Hosoya and Tomi, 2005). The RMECs 
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form complex TJs which functions to prevent the free diffusion of substances between 
circulating blood and neural retina (Hosoya and Tachikawa, 2009). The selectively permeable 
TJs in RMECs ensure correctly regulated hemodynamics and delivery of oxygen and 
metabolites (Pournaras et al, 2008).   Breakdown of the iBRB is the major cause of vision 
loss in ocular disorders such as diabetic retinopathy, sickle cell disease and cystoid macular 
edema (Brankin et al. 2005, Vinores et al. 1999).  Retinal vascular changes resulting in 
increased retinal vascular permeability represent a major pathological change in diabetic 
retinopathy (Ma et al. 2005).  
 
1.2 Outer Blood Retinal Barrier 
The Outer Blood Retinal Barrier (oBRB) is formed by a monolayer of RPE cells which lies 
between the neural retina and Bruch’s membrane, separating it from the choroid. The oBRB 
faces the photoreceptor layer of the eye on its apical side. The Bruch’s membrane separates 
the RPE from the chorio-capillaries on the basolateral side. The long apical microvilli of RPE 
cells surround the light sensitive outer segments of the photoreceptor cells establishing a 
complex of close structural interaction (Strauss, 2005). The oBRB regulates passage of ions 
and macromolecules into the photoreceptor layer and transports water and metabolic end 
products from the sub-retinal space to blood. The RPE layer also assists in development of 
retinal structures by secreting a host of growth factors required for endothelial and 
photoreceptor cell differentiation (Strauss, 2005, Adamis et al. 1993). Breakdown of the 
oBRB in conditions such as Age Related Macular Degeneration (ARMD) and Retinitis 
Pigmentosa leads to degradation of the photoreceptor cell layer (Cunha-Vaz et al. 2010, 
Vinores et al. 1995).  
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1.3 Retinal Pigment Epithelium 
The Retinal Pigment Epithelium (RPE) is a highly specialized tissue that serves an 
indispensable and multifunctional role within the eye (Strauss 2005). It comprises a 
monolayer of pigmented cells lining the basal surface of the photoreceptor layer of the neural 
retina (Fig. 1.1). Apart from forming the oBRB, the RPE cells also regulate the functioning of 
the neural retina. RPE is required for transportation of nutrients and ions between the retina 
and choriocapillaries (Kevany and Palczewski, 2010, Rizzolo et al 2007(a)). The RPE cells 
play an important role in the visual cycle by regenerating 11-cis-retinal from trans-retinal 
(Strauss 2005). The reduction in delivery of retinal to photoreceptors has been found to cause 
photoreceptor dystrophy (Seeliger et al, 1999). The photoreceptor cells require a delicate 
balance of proteins, lipids and metabolites in order to function properly. Disturbance of this 
balance leads to retinal degeneration (Strauss 2005). The photoreceptor cells undergo a daily 
renewal process in order to prevent the toxic effects of accumulated photo-oxidative 
products, by shedding 10% of their volume in the form of discs (Kevany and Palczewski, 
2010). These discs are phagocytosed by RPE cells. Breakdown in the ability of the RPE to 
degrade the photo-oxidative products is believed to be the underlining cause for degenerative 
disorders such as ARMD (Nandrot et al, 2004) and Usher’s syndrome (Fig 1.1). 
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Fig: 1.1 Photoegulatory function of RPE barrier (Image provided by Dr. Brenda Brankin) 
1.4 Tight Junctions 
The interaction between protein complexes of adjacent cells gives rise to two types of 
membrane barrier junctions – Tight Junctions (TJ) and Adherens Junctions (AJ). Among 
other components, TJs are required in the oBRB to regulate the trans-epithelial movement of 
ions and other molecules into the paracellular space (Balda and Matter, 2000). TJs provide a 
continuous seal around the apical region of the lateral membranes of adjacent cells (Citi, 
1993). When viewed under the microscope using freeze fracture electron microscopy, TJs 
appear as a ‘necklace’ of strands encircling the cells (Rizzolo et al, 2007(b)). The TJs lie on 
the apical side of the cells, close to AJs which bind the adjacent cells in the monolayer 
(Rizzolo et al., 2007 (a)). TJs constitute a barrier both to the passage of molecules and ions 
through the epithelium, and also to the free movement of proteins and lipids between the 
apical and basolateral domains of the epithelium (González-Mariscal et al., 2003). A decrease 
in epithelial transport of chloride ions has been reported to cause retinal degeneration 
(Jentsch et al, 2002). However, their function is not merely limited to their barrier properties. 
TJs play an important role in vesicle targeting, cytoskeletal dynamics proliferation and 
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transcription signalling while also defining cell polarity (Anderson et al., 2004, Tsukita et al., 
2001). 
 
Fig 1.2 Illustration showing positioning of tight junctions and adherens junctions (Source: 
Mark and Davis, 2002) 
Paracellular transport can be achieved through TJs either through membrane pores formed by 
transmembrane proteins, or via breakdown of TJs, as in the case of pathological conditions 
(Anderson and Van Itallie, 2008). The charge-selective claudin-based pores in TJs are about 
0.4nm in radius and a second non charge selective transport mechanism is achieved through 
the large discontinuities in the barrier (Anderson and Van Itallie, 2009). 
 
1.5 Tight junction proteins 
TJ barriers in the RPE layer are formed by interaction between several key membrane 
proteins. The TJs have a surprisingly complex protein composition compared to other cell – 
cell junctions and nearly 40 different proteins associated with TJs have been identified so far 
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(Anderson and Van Itallie 2009; Yamazaki et al., 2008, González-Mariscal et al. 2003). The 
earliest TJ associated proteins discovered were the Zonula Occludens (Zo) proteins (Franke, 
2009, Balda and Matter 1998). They were later identified as proteins associated with the 
cytoplasmic domain of claudins (CLDN) and occludin. Occludin was discovered later by 
Furuse et al (1993) and was shown to be able to create tight junction-like assemblies in 
normal rat kidney cells (Van Itallie and Anderson 1997). However, it was later discovered 
that there are other tight junction molecules apart from occludin, as intact TJs have been 
discovered in occludin -/- mice (Franke 2009, Saitou et al 2000). These mice survived to 
adulthood, although with several abnormalities (Saitou et al, 2000). Further research led to 
the identification of two 22kDa proteins which immuno-localized at TJs of living cells. These 
proteins were later named claudin 1 and 2. Claudins were able to form new TJs when the 
cDNA was transfected into mouse L fibroblast cells which lacked TJs completely (Franke 
2009, Furuse and Tsukita 2006, Furuse et al, 1998).  
 
With the discovery of more members of the claudin family, it was clear that the TJs were 
more complex structures than they initially appeared to be. Co-culture of mouse L fibroblast 
cells expressing claudin 1, 2 or 3 revealed that heterotypic TJs were formed by binding of 
claudin 1/3 or claudin 2/3, but not claudin 1/2 (Furuse, 1999). Occludin and Tricellulin are 
closely associated with claudins and modulate TJ strand formation (Furuse, 2010). 
  
1.6 Occludin 
Occludin was the first TJ protein to be identified and was isolated from chick liver tissue 
(Furuse et al, 1993). It is a 65kDa tetraspannin protein found localized almost exclusively in 
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tight junctions (Feldman et al. 2005, Tsukita and Furuse 1998). The tertiary structure of 
Occludin is made up of four transmembrane domains - a long C-terminal cytoplasmic 
domain; a short N-terminal cytoplasmic domain; two extracellular loops; and one 
intracellular turn (Harhaj and Antonetti 2004, Saitou et al, 2000) (Fig 1.2). The first 
extracellular loop, consisting of a high percentage of 60% tyrosine and glycine, residues is 
characteristic of occludin, although the exact physiological function remains to be elucidated 
(Furuse, 2010). The cytoplasmic carboxy-terminal of occludin interacts with Zo-1, 
establishing a link with the actin cytoskeleton (Fanning et al, 1998). 
 
Through immunoflourescence and immunoelectron microscopy techniques it was established 
that Occludin is exclusively located at the TJs of epithelial and endothelial cells (Blasig et al 
2011, McCarthy et al 1996, Furuse et al 1993). The expression of occludin correlates with 
barrier properties of the tissue (Harhaj and Antonetti, 2004). Very high expression of 
occludin in tissues such as brain endothelium and RPE results in formation of a very tight 
barrier. Over-expression of occludin in mouse L fibroblasts which lack TJs and AJs, caused 
localization of occludin into cell-cell contacts between adjacent cells, although it did not form 
fully developed strand-like TJs as observed in wild type (Furuse et al, 1998). 
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Fig: 1.3 – Schematic diagram of transmembrane protein Occludin (Dӧrfel and Huber, 2012) 
Sequencing studies have shown that the membrane topology of Occludin is well conserved 
across species (Ando-Akatsuka et al, 1996). Occludin spans the plasma membrane of 
endothelial cells of the BRB. The extracellular domain of Occludin binds to another occludin 
molecule on the adjacent cell to form the tight junction responsible for permeability barrier 
(Jin et al 2002).  The cytoplasmic terminal of Occludin associates with Zo-1 and helps in 
membrane localization of the protein while the second extracellular domain helps in 
stabilizing Occludin in the tight junction (Medina et al 2000) 
 
Occludin is naturally present in TJs in multicellular organisms and plays a role in maintaining 
the structural integrity of TJs. Over-expression of occludin in MDCK cells has been found to 
increase the trans-epithelial electrical resistance (TEER) (Tsukita and Furuse 1998, Balda et 
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al. 1996). An Occludin knock-out study performed by Saitou et al (1998) on embryonic stem 
cells showed the presence of intact tight junctions, structurally similar to that seen in wild 
type embryonic stem cells. This indicated that Occludin was not indispensable for 
maintenance of TJ integrity, and that other tight junction membrane proteins were able to 
compensate for lack of Occludin expression in tight junctions. However, Occludin -/- mice 
displayed several abnormalities, including testicular atrophy, gastric hyperplasia, thinning of 
compact bone and calcium deposits in the brain (Saitou et al., 2000). This suggested that the 
role of Occludin and TJs cannot be defined as being merely of structural nature. A knock-out 
study performed by Schulzke et al (2005) showed that the permeability of intestinal epithelia, 
measured using TEER and tests of barrier function, did not significantly alter from that of the 
wild type. However, the glandular structure of gastric corpus mucosa in occludin -/- mice 
exhibited a complete loss of parietal cells, and also mucus cell hyperplasia, resulting in a loss 
of ability to secrete acid. This demonstrated that occludin was essential for differentiation of 
gastric epithelia. 
 
The role of Occludin in the formation of tight junctions has been investigated widely. When 
occludin expression was induced in NRK (Normal Rat Kidney) cells and Rat-1 fibroblasts, 
which lack endogenous occludin and tight junctions, it co-localized with Zo-1 to form cell-
cell adherens-like junctions (Van Itallie and Anderson, 1997).  
 
1.7 The Claudin Family of Tight Junction Proteins 
Among the several molecular components of TJs now identified, the claudins, a family of at 
least 24 different proteins, are now believed to comprise the backbone of TJs (Overgaard et al 
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2011, Lal-Nag and Morin, 2009, Furuse and Tsukita, 2006, Firth 2002). Claudins are tetra-
spanning transmembrane proteins of molecular weight range between 20-25kDa, with two 
extracellular and one intracellular loop. They have been broadly classified into two groups 
based on the degree of sequence similarity – “classic claudins” which include claudins 1 to 
10, 14, 15, 17 and 19 and “non-classic claudins” which include claudins 11 to 13, 16, 18 and 
20 to 24 (Krause et al, 2009). Of these, 23 have been identified to have functional 
significance in humans (Katoh and Katoh, 2003). Occludin was the first protein identified to 
localize at TJs (Tsukita et al., 2008). Until the discovery of Claudins, occludin was 
considered to be solely involved in TJ formation. However, targeted disruption of the 
occludin gene in embryonic stem cells did not prevent formation of intact TJs (Saitou et al., 
1998), which indicated involvement of other proteins in barrier formation. This led to the 
discovery of two membrane proteins of ~22kDa weight, which bore no sequence similarity to 
Occludin. The first two Claudins identified - Claudin-1 and Claudin-2 - were isolated from 
fractions of chick liver (Harhaj and Antonetti 2004, Furuse et al., 1998). The intrinsic ability 
of Claudins to form TJs was observed when their expression in fibroblasts was found to 
induce the formation of singular TJ strands in the otherwise non-adherent cell line (Furuse et 
al., 1998 (a)). 
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Fig 1.4 Schematic representation of Claudin Monomer showing four transmembrane 
domains (TM1, 2, 3 and 4), two extracellular loops and one intracellular turn. (Source: Lal-
Nag and Morin 2009) 
 
Claudins are integral membrane proteins containing four hydrophobic transmembrane 
domains and two extracellular loops (Fig 1.3) (Gupta and Ryan 2010). The carboxy- and 
amino- terminal domains are cytoplasmic and interact with Zo-1 in the cytoplasm. The amino 
terminus is relatively short while the carboxy-terminus is variable in length in claudins (Lal-
Nag and Morin, 2009). The first extracellular loop has several charged amino acids and is 
thought to influence paracellular charge selectivity (Lal-Nag and Morin 2009, Colegio et al 
2002). Two highly conserved cysteine residues in the first extracellular loop (Fig 1.3) are 
thought to play an important role in protein stability by forming intramolecular disulphide 
bonds (Angelow and Yu 2009, Angelow, Ahlstrom and Yu, 2008). Phosphorylation of serine 
or threonine residues in the carboxy- terminal of claudins may play a role in membrane 
localization of claudins to form TJs (Furuse, 2010). 
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Claudins 1 and 2 have been identified as being most crucial for formation of the tight 
junctional barrier (Furuse et al. 1998(b)). Introduction of claudin-1 and claudin-2 genes into 
TJ-lacking fibroblasts caused the formation of a network of TJ like strands very similar to 
epithelial and endothelial TJs (Furuse M et al 1998). Co-expression of different claudins into 
fibroblasts revealed that TJ strands are comprised of mosaics of different claudins, forming 
homotypic and heterotypic interactions between cells and homomeric and heteromeric 
complexes in individual cells, although their compatibility is dependant on the right 
combination of claudins (Furuse, 2010). 
 
Other in vivo functions of claudins are being studied using gene knock-outs, over- or under-
expression in epithelial cells, and by the study of human disease phenotypes resulting from 
claudin mutations (Turksen and Troy 2011, Angelow et al. 2008). Other members of the 
claudin family have been identified to have several other functions including paracellular 
transport (Will et al 2008). For instance, claudin-16, also known as paracellin-1, is important 
for electrolyte handling in kidney, apart from playing a structural role in the organ (Weber et 
al. 2001, Simon et al. 1999). Key functions of claudins identified to date, along with their 
functions are shown in Table 1.1. 
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Table 1.1 – Overview of properties, distribution, function and pathologies of claudins 
Claudin Size (Da) Key Points 
Claudin - 1 22744 
Plays a key role in epidermal TJ barrier formation along with 
claudin-2. Co-localizes with occludin to forms a permeability 
barrier. Important in BBB and BRB formation. 
Claudin – 2 24549 
Forms discontinuous strands when expressed individually. Co-
expressed with claudin-1 and plays an important role in embryonic 
development and TJ formation. Also functions as cationic pore 
protein and decreases TEER when over-expressed in SMIE cells. 
Claudin – 3 23319 Over-expressed in ovarian cancers along with claudin-4.  
Claudin – 4 22077 
Directly interacts with TJ proteins Zo-1, 2 and 3. Expressed in 
many foetal and adult tissues, predominantly in intestine, kidney 
and lung. Claudin-4 is an integral membrane protein and forms an 
important component of TJs. Over-expression leads to increase in 
TEER. Over-expressed in several carcinomas, except in pancreas. 
Cardiovascular and cytoskeletal abnormalities implicated due to 
claudin-4 gene deletion in Williams-Beuren Syndrome. 
Claudin – 5 23147 
Primarily found in human endothelial TJs and colonic epithelium. 
Co-localizes with occludin and assists in TJ sealing. Plays a 
significant role in BBB formation. 
Claudin – 6 23292 Present in embryonic kidney, but disappears in adult kidney. Identified as a biomarker for abnormal skin conditions. 
Claudin – 7 22390 
Biomarker for breast and neck carcinomas. Acts as a channel 
protein for paracellular Na+ ion transport. Found in nephrons, 
colonic and tonsillar epithelia. 
Claudin – 8 24845 
Found in colonic epithelia and kidney. Found to reduce 
paracellular cation permeability. Claudin-8 is down-regulated in 
Crohn’s disease. 
Claudin – 9 22848 Found in inner ear and embryonic kidney. Thought to play a role in paracellular permeability changes in embryonic epithelia. 
Claudin – 10 
24251 (a) 
24488 (b) 
Two claudin-10 variants transcribed from different start sites. 
Different amino termini. Preferential paracellular permeation of 
anions (a) or cations (b) 
Claudin – 11 21993 
Endocochlear potential regulation. Found to reduce paracellular 
cation permeability in MDCK. Down-regulation found to cause 
deafness, male sterility and hind limb weakness in mice. 
Claudin – 12 27110 Found in inner ear, brain endothelium and colon 
Claudin – 13 Absent in humans. 
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Claudin – 14 25699 
Found in inner ear and sensory epithelium of organ of corti in 
mammalian ear. Down-regulation causes non-syndromic deafness 
and degeneration of cochleal hair cells.  
Claudin – 15 24356 Found in kidney endothelial cells and intestine. Found to increase 
cation permeability.  
Claudin – 16 33836 Primarily found in kidneys. N terminal is 73 amino acids long.  
Claudin – 17 24603 mRNA identified in human kidney and taste receptor cells. 
Claudin – 18 
27856 
27720 
Two variants formed by alternate transcription start sites. Different 
amino termini. Down-regulated in gastric cancer. 
Claudin – 19 
23229 
22076 
Two variants formed by alternative splicing. Different carboxy 
termini. Found in kidney and retinal cells. Up-regulation increases 
TEER, reduces cation permeability. Adversely affects nerve 
conduction when down-regulated. 
Claudin – 20 23515 Found in skin. 
Claudin – 21 25393 Down-regulated in chondrosarcoma, liver cancer. 
Claudin – 22 25509 Found in human trachea. Down-regulated in breast cancer. 
Claudin – 23 31915 The C-terminus is 111 amino acid long. Down-regulated in intestinal type gastric carcinomas. 
Claudin – 24 22802 Gene identified. No expression or knockout studies found. 
(Source: Gupta and Ryan 2010, Findley and Koval, 2009, Lal-Nag and Morin 2009, Furuse 
2009, Florian et al 2003) 
 
Biochemical diversity among members of the Claudin family underlies differences in TJ 
structure and function in different tissues and cell types (Van Itallie and Anderson, 2004). 
Individual cells express more than one Claudin protein. Studies show that claudins form the 
functional backbone of TJ pores and play a very active role in paracellular transport (Table 
1.1). These properties may provide a route to therapeutic manipulation of TJ structure for 
delivery of pharmacological agents. 
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1.8 Zonula occludens (Zo) proteins 
The Zo proteins are a group of high density proteins which interact with the cytoplasmic 
terminals of occludin and claudins (Anderson and Van itallie, 1995). Zo proteins are best 
characterized among the “cytoplasmic plaque proteins” in the tight junctional complex. Three 
Zo proteins have been identified and named as Zo-1, Zo-2 and Zo-3. They belong to a family 
of Membrane Associated Guanylate Kinases (MAGUKs) (Mitic and Anderson 1998, 
Anderson et al, 1995).  In addition to the core domain structure consisting of PDZ, SH3 and 
GuK domains characteristic of MAGUKs, the Zo proteins have a distinctive carboxy- 
terminal with splicing domains, acidic- and proline-rich regions (González-Mariscal et al. 
2000). 
 
Among the Zo proteins, Zo-1 exists in two isoforms, formed by alternative splicing, 
depending on the presence or absence of an 80 amino acid domain termed α. Zo-1(α+) is 
found in most epithelial cells and Zo-1(α-) is found in endothelial cells and certain highly 
specialized epithelial cells (Van Itallie and Anderson, 1998). Although this helps in molecular 
distinction in TJs, the actual function of the α domain remains unclear. 
 
Zo-1 and Zo-2 proteins play a pivotal role in the final establishment of belt-like adherens and 
tight junctions (Ikenouchi et al, 2007). The N-terminus of Zo proteins associate with 
cytoplasmic termini of occludin (Fanning et al., 1998) and Claudins, stabilizing their 
positioning in the tight junctions. The C-terminus of Zo proteins bind to actin, and thus act as 
scaffolds binding the tight junction proteins to the cytoskeleton (Umeda et al., 2006, Fanning 
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et al., 1998). Zo-3 shows epithelial-specific tight junction localization in a Zo-1/2-dependant 
fashion (Tsukita et al., 2009, Inoko et al, 2003). 
 
Functional significance of Zo-1 in TJ formation was analyzed by ablating Zo-1 expression 
through RNA interference or deletion of the gene by homologous recombination. Absence of 
Zo-1 did not prevent formation of the TJ barrier, although it delayed its formation (McNeil et 
al., 2006, Umeda et al., 2004). Complete absence of Zo-1, 2 and 3 proteins in mouse EpH4 
cells resulted in complete elimination of TJs on confluence (Umeda et al., 2006) although the 
cells were well polarized. 
 
1.9 Adherens junctions 
The classical cadherins mediate specific adhesion at intercellular adherens junctions. The 
adherens junctions (AJ) are formed by homophilic cadherin interactions in adjacent cells. AJs 
play a significant role in cell polarization and differentiation of epithelial cells, and calcium-
dependent cadherin-based adherens junctions organise microfilaments to the plasma 
membrane in polarized cells (Green 2010). The carboxy-terminal of cadherins in AJs binds 
cytoplasmically to P120 and β-catenin (Shapiro and Weis, 2009) which in turn bind to the 
actin cytoskeleton through α-catenin (Meng and Takeichi, 2009). 
 
1.10 Ocular diseases and abnormal RPE 
The TJ, which is the most apical component of the junctional complex, represents the 
anatomic substrate of the outer blood retinal barrier (Jin et al., 2002). Disruption of transport 
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mechanisms of the RPE leads to photoreceptor degeneration. For instance, disruption of 
epithelial chloride ion transport leads to loss of transepithelial potential in RPE. This results 
in an inability to extrude lactic acid from photoreceptors, leading to metabolic stress and 
eventual breakdown of the photoreceptor layer (Bosl et al., 2001). The RPE layer plays a 
major supportive role in maintaining the delicate metabolic balance required for functioning 
of photoreceptor cells (Strauss, 2005).  
 
1.10.1 Age Related Macular Degeneration (AMD) 
AMD is the leading cause of blindness worldwide, in the population above 50 years of age 
(Chappelow and Kaiser 2008, Friedman et al 2004, Klein et al, 2004). A recent report by 
WHO in 2009 lists AMD as one of the primary causes for vision loss worldwide. AMD is a 
multifactorial disease which affects the RPE-choroid interface in the macula (Strunnikova et 
al 2010).  
 
The ocular structures involved in AMD are photoreceptor cells, neurons in the outer retina, 
the RPE, Bruch’s membrane and choriocapillaries (Bird 2010). Metabolic interdependency of 
these tissues increases the risk of vision loss if any one of these structures is affected. AMD is 
characterized by degenerative changes in the macula, therefore leading to central vision loss 
and loss of visual acuity. A reduced capability to absorb light energy leads to the cascade of 
events leading to AMD (Strauss, 2005).  
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Fig 1.5 Development and Progression Pathway of AMD 
Based on the progression of disease, AMD has been divided into ‘dry’ and ‘wet’ types (Fig 
1.5). The earliest symptom and pathological feature of dry AMD is accumulation of photo-
oxidative residue (drusen) beneath the RPE layer and inside the Bruch’s membrane (Strauss 
2005, Handa et al 1999, Docchio et al. 1991). A small amount of drusen is found in healthy 
individuals over the age of 50, but the presence of large or numerous drusen confers 
significant risk for AMD (Patel and Chan, 2008).  
 
The presence of large and confluent drusen leads to inflammatory condition known as 
Cystoid Macular Edema (Fig 1.4). It also paves way for the establishment of large diffusion 
barriers between the RPE and choroid. This may lead to development of areas with reduced 
supply of oxygen and glucose (Strauss 2005, Frank 1997). Hypoxic stress thus induced leads 
to degeneration of photoreceptors in drusen-covered areas (Coleman et al, 2008). In a more 
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severe case, this stimulates hypoxia-induced secretion of VEGF, and suppression of PEDF 
secretion, leading to choroidal neovascularisation (Klein et al, 2004). Choroidal 
neovascularisation is the hallmark of wet AMD (Chappelow and Kaiser, 2008) and leads to 
an increase in intraocular pressure and may cause the newly formed capillaries to break (Fig 
1.6). Intra-ocular bleeding is a major cause for vision loss in wet AMD (Strauss, 2005). Wet 
AMD is also known as ‘exudative’ or ‘neovascular’ AMD. 
 
Fig 1.6 Healthy Macula versus macula with wet AMD (Source: Genentech) 
VEGF-A over-expression is important for progression and development of AMD (Witmer et 
al., 2003). Therefore, control of VEGF and its receptors is looked at as an important 
therapeutic target for control of AMD.  
 
1.10.2 Retinitis Pigmentosa 
Retinitis Pigmentosa (RP) is a group of inherited genetic eye diseases characterized by 
gradual degeneration of the outer retinal layer leading to vision loss (Hamel 2007). It 
generally affects the peripheral vision with other complications such as macular edema 
_______________________________________________________________ Introduction 
 20 
affecting central visual acuity (Sahel et al, 2010). RP may be inherited as an autosomal 
dominant, autosomal recessive, X-linked recessive or digenic traits (Wang et al. 2001, 
Humphries et al. 1990). RP is characterized by primary degeneration of rod photoreceptors 
and secondary degeneration of cone cells in the retina (Campbell et al, 2006(a)). The 
photoreceptor layer undergoes a constant renewal and sheds cytoskeletal protein, photo-
oxidative residue and rhodopsin-rich ‘discs’ which are phagocytosed by the underlying RPE 
layer (Strauss, 2005). RP may involve gene mutations in RPE leading to impairment of its 
photoregulatory function, or mutations which cause dysfunction of rod cells (Farrar et al. 
2002). Degeneration of rod outer segments leads to the presence of deposits of pigmented 
granules in the outer retina (Hamel 2009, Hamel 2007). A gene knockout study in mice 
involving targeted disruption of the Rhodopsin gene Rho (-/-) showed disruption of AJs in the 
outer retina, in 6 week old Rho (-/-) mice (Campbell et al. 2007).  
 
Key therapeutic approaches for Retinitis Pigmentosa include using pluripotent stem cells to 
differentiate into functional ocular cells that can replace damaged RPE and/or photoreceptor 
cells (Rowland et al. 2011).  
 
1.11 Diseases of iBRB – Diabetic Retinopathy (DR) 
Diabetes leads to a wide array of complications including kidney failure, vascular disease, 
peripheral nerve degeneration and vision loss (Antonetti et al 1999).  Diabetic retinopathy is 
the leading cause of blindness in the working age population in the USA causing 12000 to 
24000 new cases of blindness every year (Whitmire et al. 2011, Klein et al. 2009). Increased 
vascular permeability leading to macular edema and endothelial cell proliferation is the 
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hallmark of DR (Mitamura et al, 2005). The underlying metabolic pathways leading to 
development of DR is not completely understood. However, causes attributed to the 
pathogenesis and progression of DR include chronic hyperglycemia (Whitmire et al, 2011), 
formation and accumulation of AGEs (Takeuchi et al 2010, Stitt, 2003) and oxidative stress 
(Frey and Antonetti, 2011). 
 
The two stages of progression of DR are classified into “Non-Proliferative” (NPDR) and 
“Proliferative” (PDR). Microaneurysms develop in the retinal vasculature leading to retinal 
haemorrhages and fluid leakage in the retina. Development of macular edema leads to a 
reduction in functionality of RPE cells to remove fluid from the retina. NPDR is prevalent in 
patients suffering from type – II diabetes (Caldwell et al, 2005). 
 
PDR is a more severe form of DR. Oxidative stress and increase in photo-oxidative reactive 
species leads to expression of Advanced Glycation End products (AGEs). RPE cells express 
active receptors (RAGE) for AGEs (Hammes et al, 1999) and express Vasculo Endothelial 
Growth Factor (VEGF) in response to AGE exposure (Lu et al, 1998). Retinal pericytes are 
reported to accumulate AGEs during diabetes (Stitt et al, 1997) which blocks retinal vessels 
thereby leading to hypoxic stress and apoptosis of retinal pericytes. Hypoxic stress and AGE-
stimulated release of VEGF and related growth factors into the retina leads to angiogenesis 
and neovascularization in the retina (Okamoto et al, 2002). Neo-vascularisation progresses 
into the vitreous cavity towards the later stages of PDR. Newly formed blood vessels are 
weak and may break, allowing blood to leak out and cloud the vitreous and impair vision 
(Caldwell et al. 2005). Formation of fibrovascular tissue in advanced stages of PDR leads to 
retinal detachment and loss of vision in patients. 
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VEGF has been identified as a critical stimulus in the pathogenesis of macular edema in 
NPDR (Wolfensberger and Gregor, 2010, Karim and Tang, 2010). VEGF antagonists have 
hence received a great deal of interest in the treatment of DR. 
 
Aims and Hypothesis 
The blood brain barrier and the blood retinal barrier are immunologically privileged and 
depend on intact barriers to partition them from the systemic circulation (Padden et al., 2007, 
Brankin et al., 1995, Allen and Brankin, 1993). It has been previously reported that 
VEGF165 has a synergistic effect on iBRB permeability, both in vitro and in vivo (Brankin et 
al., 2005). VEGF165 significantly increased BRMEC paracellular permeability, and induced 
iBRB breakdown in C57/Bl6 mice which was demonstrated by an increase in Evans 
blue/albumin permeation at the BRB (Campbell et al., 2006, Brankin et al., 2005).  
 
These findings of an increase in permeability of the iBRB by VEGF led us to 
speculate that VEGF may also modify the oBRB permeability properties. The oBRB is 
formed by the RPE cells which separate the outer layer of the neural retina from the 
capillaries of the choroid. The cardinal function of the RPE is to prevent fluid from choroidal 
vessels from entering the retina, and to control the flow of solutes and fluid from the 
choroidal vasculature into the outer retina. This strict control of fluid and solutes that cross 
the outer barrier is achieved by TJs at the RPE. Thus a breakdown in the oBRB may lead to 
an accumulation of fluid in the sub-retinal space, and to macular edema. 
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Studies carried out in conjunction with the iBRB, showed modulation of Zo-1 
expression in an animal model of retinal degeneration, the Rho (-/-) knock-out mouse 
(Humphries et al, 1977). In this work, Brankin and colleagues found an up-regulation of Zo-1 
in neural retinas of C-129 Rho(-/-) knockout mice compared to C-129 WT mice, associated 
with the retinal vasculature, and a loss of expression of Zo-1 at the Outer Limiting Membrane 
of the photoreceptors in Rho(-/-)  (Campbell et al., 2007). In view of these previous reports, 
we wished to further extend the work in this project by investigating the effects of the VEGF 
family of growth factors on BRB function. PLGF is a member of the VEGF family and 
potentiates the activity of VEGF (Hollborn et al., 2006).  Brankin and Stitt, have reported that 
PLGF induced phosphorylation of occludin on serine and tyrosine residues, and may modify 
the capacity of occludin to associate with Zo-1 at the BRB (Brankin and Stitt, 2003). 
 
The proinflammatory cytokines, TNF-α and IL-1β have been found to affect BBB and 
iBRB permeability, and may promote choroid neovascularisation (Oh et al., 1999), which is a 
sight-threatening complication of macular diseases, including ARMD. Previously, it has been 
shown that IL-1β and TNF-α affected the TJ expression and that these cytokines increased 
phosphorylation of occludin on threonine residues in balb/c microvascular endothelial cells, 
and caused a down-regulation of occludin expression (Brankin and Padden, 2004). Thus, in 
this project, we wished to further investigate whether IL-1β and TNF-α would have an effect 
on the oBRB.  
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Hypotheses 
1. Overall it is hypothesised that key components of the TJ and AJ of the RPE may 
become compromised following treatment with growth factors and cytokines, 
facilitating breakdown of the oBRB and retinal dysfunction. 
2. VEGF165, produced in high amounts by cells in the neural retina, may affect Zo-1 or 
occludin expression and localisation at the oBRB, leading to oBRB dysfunction.  
3. PLGF is a member of the VEGF family and may modify expression levels of TJs 
which will affect RPE function.     
4. Chronic, low-grade inflammatory processes such as cystoid macular edema may 
contribute to the pathogenesis of ARMD.  It is hypothesised that TNF-α produced 
locally at the RPE by infiltrating macrophages in ARMD may modulate TJ expression 
and disrupt the oBRB. Changes in expression or localisation of TJs may affect RPE 
polarity as the TJs of RPE are anchored to the actin cytoskeleton of RPE, and interact 
with signalling molecules and are important in establishment of cellular polarity 
5. It is hypothesised that IL-1β affects expression and distribution of the TJ junctional 
proteins occludin, Zo-1 and the claudin family. This may lead to loss of RPE function, 
breakdown in the ability to degrade the photo-oxidative products, retinal edema and 
oBRB breakdown.  Claudins regulate diffusion across the paracellular pathway by 
determining ion selectivity and electrical resistance of the junction, and they may be 
modulated by Il-1β, giving rise to oBRB breakdown. 
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Project Aims 
The research presented in this thesis will focus on the BRB in health and disease and the 
effects of growth factors and cytokines on oBRB function which will be investigated using an 
in vitro model, human retinal pigment epithelial cells. Specifically the following will be 
determined:  
I. Tight/adherens junction expression at the oBRB, including occludin, Zo-1, beta catenin, 
claudins 1, 2, 3 and 4. 
II. Effects of vitreal growth factors VEGF and PLGF on oBRB integrity 
III. Effects of pro-inflammatory cytokines, which are elevated in ocular disorders, on RPE 
function as determined by TJ expression and localisation at the oBRB. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 2 
 
Materials and Methods 
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 2.1 Materials 
2.1.1 Materials for cell culture and cell treatment 
2.1.1.1. Cell types used:  
Human Retinal Pigment Epithelial Cells (ARPE-19) were obtained from American 
Type Culture Collection (ATCC, Manassas, VA, USA) 
Human Brain Endothelial Cells (Endo Balbc) – were a gift from Dr. Brenda Brankin, 
School of Biological Sciences, Dublin Institute of Technology, Dublin, Ireland. 
 
2.1.1.2. Materials 
Nunc cell culture flasks 25cm2 (Cat no: TKT-130-170F) and 75cm2 (Cat no: TKT-
130-210T) (Fischer scientific, Dublin – 2) 
Cell Star cell culture plates (6 well) Greiner Bio-One (Cat no: 657160, Lot no: 
E1008003) 
Nunc Lab-Tek Chamber Slide System and Lab-Tek chambered coverglass (Cat no: 
177429) 
Dulbecco’s Modified Eagle’s Medium (DMEM): Sigma Aldrich (Wicklow, Dublin – 
24) Nutrient Mixture F12- Ham (DMEM / F12 1:1) with L- glutamine (Cat no: 
D8437, Lot No: 048K2413, 097K2406, RNBB0033) 
Sigma Aldrich Protease inhibitor cocktail (Cat no: P8340) 
Adult Bovine Serum – Sigma Aldrich (Wicklow, Dublin) (Cat no: B9433, Lot No: 
018K8413) 
Trypsin-EDTA [0.25% (w/v) Trypsin 0.02% (w/v) EDTA] Sigma Aldrich (Wicklow, 
Dublin) (Cat no: T4049, Lot no: 10A725, 097K2336) 
Insulin Transferrin Selenium (ITS) media supplement – Sigma Aldrich (Cat no: 
I3146, Lot no: 069K8409) 
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Penicillin Streptomycin solution – Sigma Aldrich (Wicklow) (Cat no: P4458) 
Amphotericin – B Sigma Aldrich (Wicklow, Ireland) (Cat no: A4888, Lot 
no:117K4016) 
Dimethyl Sulphoxide (DMSO) – Sigma Aldrich (Cat no: D2650) 
Vascular Endothelial Growth Factor (VEGF) Sigma Aldrich (Wicklow, Ireland) (Cat 
no: V7259, Lot: 075K1601) 
Placental Growth Factor – Invitrogen (Biosciences, Ireland), Cat no: PHG0296 
Interleukin 1-beta (IL-1β) – Sigma Aldrich (Wicklow, Ireland) (Cat no: I2393) 
Tumor Necrosis Factor – Alpha (TNF - α) Sigma Aldrich (Wicklow, Ireland) (Cat no: 
T0157, Lot: 114K1429) 
Endostatin – Sigma Aldrich (Wicklow, Ireland) (Cat no: E8154) 
Disposable Cell Scraper – Fisherbrand – Fischer Scientific (Dublin 2) (Cat no: 08-
773-2)  
BD Plastipak Green needle and Syringe – Becton Dickinson (Spain) (Lot: 0512006) 
 
2.1.1.3. Solutions used: 
Phosphate Buffered Saline (PBS) – 8.1mM di-sodium hydrogen phosphate 
(Na2HPO4), 1.7mM sodium di-hydrogen phosphate (NaH2PO4), 27.4mM sodium 
chloride (NaCl) per litre, adjusted to pH 7.4 and sterilized by autoclaving. 
 
2.1.2. Materials for Protein Analysis 
96 well flat bottom ELISA plates – Nunc – Fischer Scientific Ireland (Cat No: TKT-
180-070U) 
Bradford Reagent – Sigma Aldrich (Wicklow) (Cat no: B6916, Lot no: 033K9279) 
ELISA plate reader - Labsystems Multiscan Plus  
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Bovine Serum Albumin – Sigma Aldrich (Wicklow) (Cat no: A7030, Lot No. 
038K0704). Protein standards ranging from 100µg/ml to 1000µg/ml made up using 
distilled de-ionized water. 
 
2.1.3 Materials for SDS PAGE 
Protein Samples prepared from cell extracts as detailed in section 2.1.2 
Sigma Aldrich acrylamide / bis acrylamide 30% (w/v) solution (Cat no: A3699, Lot 
no: 097K6067) 
N,N,N’,N’ Tetramethylethylenediamine (TEMED) – Sigma Aldrich (Wicklow) (Cat 
no: T9281, Lot no: 93H0857) 
Ammonium persulphate – Sigma Aldrich (Wicklow) (Cat no: A3698, Lot No: 
022K1258) 
Trizma base SigmaUltra - Sigma Aldrich (Wicklow) (Cat no: T6791, Lot no: 
083K5417) 
Sodium Dodecyl Sulphate – BDH Laboratory supplies (Poole, England) (Cat no: 
301754L, Lot no: ZA2003410-649)  
Glycine (Molekula) (Cat no: M10760576, Lot no: 51613) 
Bromophenol blue – Sigma Aldrich (Cat no: B5525, Lot no: 124H3631) 
Glycerol – (Riedel-de Haen) – Lennox Chemical Supplies (Dublin) (Cat no: 33224, 
Lot no: 72610) 
3-[(3-Cholamidopropyl)dimethylammonio]-1-propanesulfonate (CHAPS) – GE Life 
sciences (United Kingdom) (Cat no: 17-1314-01) 
 
2.1.3.1 Solutions used 
Resolving Gel Stock – 1.5 M Tris containing 0.4% (w/v) SDS adjusted to pH 8.8  
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Stacking Gel Stock – 0.5M Tris, 0.4% (w/v) SDS adjusted to pH 6.8 
Running Buffer (10-fold concentrate) 1L: 248mM Tris, 1.92M Glycine, 10g SDS 
adjusted to pH 8.6 
4x Sample buffer (100ml): 0.5M Tris (pH 6.6), 16g SDS, 20% (v/v) Glycerol, 16mg 
Bromophenol Blue, 10% (w/v) CHAPS.  
Butanol 95% (v/v) 
Ammonium persulphate 0.1% (w/v) 
 
2.1.4. Materials for Western blotting 
Semi-dry blotting apparatus – Appolo Laboratories, Sweden 
Alpha Imager FC™ 1-D digital analysis software (Alpha Innotech) 
AlphaImager HP™ Gel imaging system (Alpha Innotech) – Cell Biosciences  
Whatman Protran BA83 Nitrocellulose membrane – Sigma Aldrich (Wicklow, 
Ireland) (Cat no: Z670960, Lot No: 8558862) 
Ponceau S Solution – Sigma Aldrich (Wicklow) (Cat no: P7170, Lot no: 093K4356) 
Albumin Bovine Serum, Fraction V – Sigma Aldrich (Wicklow) (Cat no: A9647, Lot 
no: 038K0704) 
Tween 20 for electrophoresis – Sigma Aldrich (Cat no: P5927, Lot no: 043K01541) 
Western Super Signal West Pico Chemiluminescent Substrate - Pierce 
Western Super Signal West Pico Chromogenic Substrate BCIP / NBT – Pierce 
Novex AP Chromogenic Substrate (BCIP / NBT) Invitrogen (Biosciences, Ireland) 
(Cat no: WP20001, Lot no: 622918) 
Methanol (Riedel-de Haen) – Lennox Laboratories Ltd. (Dublin) 
MagicMarkTM XP Western Standard – Invitrogen (Biosciences, Ireland) (Cat no: 
LC5602, Lot no: 462876). 
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2.1.4.1. Antibodies used 
Sigma Aldrich – Monoclonal anti β-Actin antibody produced in mouse (Cat No: 
A1978, Lot No: 016K4817) 
Zymed Labs –Monoclonal anti Zo-1 antibody produced in mouse 100ug (Cat No: 33-
9100, Lot No: 60605689) 
Sigma Aldrich – anti rabbit IgG (whole molecule) – peroxidase-conjugated antibody 
developed in goat (Cat No: A6154, Lot No: 055K6015) 
 
2.1.4.2. Solutions Used 
Transfer Buffer – 25mM Tris, 20% (v/v) methanol, 20% (w/v) glycine; adjusted to pH 
7.0. 
Tris Buffered Saline (TBS) – 50mM Tris, 0.15M Sodium Chloride, adjusted to pH 7.0 
Blocking Solution – 5% (w/v) Bovine Serum Albumin (BSA) dissolved in TBS 
Wash Buffer – 0.2% (v/v) Tween20 in TBS (pH 7.0) 
Western Blot Stripping solution – 0.01mM Tris, 10% SDS, 0.001% (v/v) β-
mercaptoethanol. 
 
2.1.4.3. SDS PAGE Resolving Gel preparation 
Percentage 7.5% 12% 14% 
Gel stock 5 ml 5 ml 5ml 
Water 10 ml 8.4 ml 5.7ml 
Bis-Acrylamide (30%) 5 ml 6.6 ml 9.3ml 
Ammonium Persulphate (0.1%) 200µl 200µl 200µl 
TEMED 20µl 20µl 20µl 
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2.1.4.4. 4% Stacking Gel preparation 
Stacking Gel Stock – 1.5ml 
Water – 3.6ml 
30% (w/v) Bis acrylamide – (0.9%) - 900µl 
Ammonium persulphate 0.1% (w/v) – 100µl 
TEMED – 20µl 
 
2.1.5. Materials for Immunoflourescence 
Occludin and Zo-1 primary antibodies, as outlined in section 2.1.4.1 
Biotinylated mouse immunoglobulin (Vector Labs) provided with Vectastain 
universal ABC kit (Cat no: PK6200) 
Vectastain Flourescein Streptavidin – Vector Labs (Cat no: SA-1200) 
Vectastain Texas Red Streptavidin – Vector Labs (Cat no: SA-5006) 
Vectastain Flourescence mounting medium with DAPI – Vector Labs (Cat no: H-
1200) 
Lab-Tek 2 well chamber slides with coverglass – Nunc – (Cat no: 177380) 
Blocking solution – 3% (w/v) BSA in PBS 
Wash solution – 0.2% (v/v) Tween20 in Phosphate buffered saline 
100% Methanol 
 
2.1.6 Materials for immunohistochemistry 
Paraffin-embedded tissue sections – gift from Dr. Helen Lambkin, School of 
Biological Sciences, Dublin Institute of Technology, Dublin, Ireland.  
Histolab Xylene – (Cat no 02080) 
Histolab 99.5% Ethanol, Histolab 95% Ethanol and Histolab 80% Ethanol (all v/v) 
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Sodium Citrate – Fischer Scientific (Dublin, Ireland) (Cat no: BP327-1) 
Vector Labs VECTASTAIN Universal ABC staining kit: Mouse IgG (Cat no: 
PK6200) 
Vector Labs DAB Peroxidase substrate kit (Cat no: SK 4100) 
DPX and coverslips 
 
2.1.6.1 Solutions used 
Citrate buffer – 10mM Sodium Citrate in 1.0 L of double distilled water adjusted to 
pH 6.0 
Blocking reagent – 5% (v/v) normal horse / goat serum in PBS 
3% (v/v) hydrogen peroxide prepared by diluting 1ml of 30% (v/v) hydrogen peroxide 
in 9mls of distilled water. 
ABC reagent – prepared according to manufacturer’s instructions 
DAB reagent – prepared according to manufacturer’s instructions. 
 
2.1.7. Materials for 2-D Electrophoresis 
IPG Buffer – pH 3.0 – 10.0 (GE Healthcare LifeSciences, UK) (Cat no: 17-6000-87) 
Storage: 4oC 
Immobiline Dry Strip IPG Gel strips – pH 3-10, Length 13cm (GE Healthcare 
LifeSciences, UK) (Cat no: 17-6001-14) storage: -20oC 
PlusOne Dry Strip cover fluid – 1L (GE Healthcare LifeSciences, UK) (Cat no: 17-
1335-01) 
PlusOne CHAPS – 1g (GE Healthcare LifeSciences, UK) (Cat no: 17-1314-01) – 
Storage: 4oC 
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PlusOne Dithiothreitol (DTT) – 1g (GE Healthcare LifeSciences, UK) (Cat no: 17-
1318-01) – Storage: 4oC 
Coomassie brilliant blue R250 (Sigma Aldrich, Wicklow) (Cat no: 27816) 
Bromophenol Blue – Sigma Aldrich (Cat no: B5525, Lot no: 124H3631) 
DeStreak Rehydration Solution – pH 3-10 (GE Healthcare LifeSciences, UK) (Cat no: 
17-6003-19) storage: -20oC 
Sigma ProteoSilverTM Silver Staining Kit – Sigma Aldrich (Wicklow) (Cat: 
PROTSIL1) 
Refrigerated centrifuge (Eppendorf 5417R) 
pH meter (Hanna instruments pH 210 microprocessor) 
Balance (Mettler Toledo, AB204) 
Vortex (Rotamix Hoock and Tucker Instruments Ltd) 
Immobiline drystrip reswelling tray (GE Life sciences, UK) 
Ettan IPGphor II Isoelectric Focusing System, Ettan IPGphor Manifold, Electrodes 
and paperwicks (GE Lifesciences, UK) 
Gel apparatus consisting of – Gel electrophoresis box (ATTO - MSC), Glass plates 
16x14 cm and 2mm thick, rubber gaskets, bulldog clips and combs 
Power pack (0-400V, 0-200mA) (Vokam SAE 2761) 
Staining and destaining trays 
Orbital mixer (KS 125 basic IKA Labortechnik) 
Tissue culture hood (EHRET Reinraumtechnik) 
Scanjet 5300C (Hewlett Packard) 
Imaxia Gelfox™ 3.0 (Alpha Innotech) 
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2.1.7.1 Solutions Used 
Bromophenol blue stock solution – 1% (w/v) bromophenol blue and 0.6% (w/v) 
Trizma base in double distilled water. 
Rehydration stock – 7M Urea, 2M Thiourea, 15mM DTT, 1% Pharmalytes, 4% 
Triton-X 100, 0.002% (v/v) bromophenol blue stock solution in distilled water. 
Divided into 2.5ml aliquots and stored at -20oC. 
Equilibration solution – 0.05M Trizma base, 6M Urea, 30% (v/v) glycerol, 1% (w/v) 
SDS, 32mM DTT (Buffer – I), 0.002% (v/v) bromophenol blue stock solution. 
Coomassie blue stain – 0.025% (w/v) Coomassie brilliant blue R250 (Sigma Aldrich), 
40% (v/v) methanol, 7% (v/v) acetic acid made up to 2L using double distilled water 
and filtered through filter paper. Stored at room temperature. 
Destain solution 1 – 40% (v/v) methanol and 7% (v/v) acetic acid made up to 1L 
using double distilled water. Stored at room temperature. 
Destain solution 2 – 5% (v/v) methanol and 7% (v/v) acetic acid made up to 1L using 
double distilled water. Stored at room temperature. 
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2.2. Methods 
2.2.1. Cell Culture 
ARPE-19 is a spontaneously arising retinal pigment epithelia (RPE) cell line derived 
in 1986 from the normal eyes of a 19-year-old male. These cells form stable 
monolayers, which exhibit morphological and functional polarity. ARPE-19 expresses 
the RPE-specific markers CRALBP and RPE-65. The cells are diploid and can be 
carried for over 30 passages. Progeny were found to undergo an additional 48 
population doublings in longevity trials performed during characterization at ATCC. 
The ARPE-19 cells were bought from ATCC and used at passage numbers less than 
30. 
 
The ARPE-19 cells were removed from liquid nitrogen storage and thawed quickly to 
retain viability. They were cultured in Dulbecco’s Modified Eagle’s Medium F12 
HAM (Sigma Aldrich) containing 10% (v/v) Adult Bovine Serum (Sigma Aldrich), 
1% (w/v) penicillin-Streptomycin(Sigma Aldrich)  and 250µl ITS media supplement 
(Sigma Aldrich). Cells were propagated in T25 cell culture flasks (Corning) with 5ml 
of 10% (v/v) complete medium and incubated at 37oC with 5% carbon dioxide. The 
medium was changed every 3-4 days until cells achieved desired confluence. 
 
A flask of confluent cells was taken from the incubator. The cells were washed 3 
times with sterile PBS and then 1ml of 0.25% (v/v) Trypsin EDTA (Sigma Aldrich) 
was added to the flask. The flask was then incubated at 37oC for 10 minutes to allow 
trypsinisation. The cells were observed under the microscope to check whether 
trypsinisation was complete and 2.0 mls of complete medium was added to the flask 
to stop the reaction. The cells were then pipetted into a sterile 15ml centrifuge tube 
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and pelleted at 1000rpm for 10minutes. The supernatant was aspirated from the tube 
and the pellet re-suspended in 1.0 ml of fresh medium. The cells were then distributed 
evenly into 3x T25 flasks, each containing 5.0 ml of 10% (v/v) complete medium. 
This process was repeated until the required amount of cells were obtained 
 
2.2.2. Growth factor treatment and extraction 
Confluent cultures were washed 3 times with sterile PBS and incubated in 
serum free medium for 6 hours. Following this, appropriate amounts of growth factors 
were added to the flasks in serum free medium and incubated for a further 24 hours at 
37oC. 
Growth factor treated RPE cells were washed 3 times with PBS to remove any 
traces of media. The cells were scraped from the flask and homogenized using a 21-
gauge needle in extraction buffer containing 62.5mM Tris, 2% (w/v) SDS, 10mM 
DTT and 10% (v/v) protease inhibitor cocktail (Brankin B et al. 2005). The cell lysate 
was then centrifuged at 14,000 rpm for 20 minutes at 4oC. The supernatant was 
removed and used for protein analysis.  
 
2.2.3. Protein Analysis 
Six different BSA protein standards ranging from 0.1 – 1mg/ml were 
prepared. To perform the assay, 10µl of each BSA standards and test samples were 
pipetted in duplicate into a 96-well flat bottom ELISA plate followed by addition of 
200µl of Bradford Reagent (Sigma). The samples were allowed to mix on a shaker for 
20 minutes. It was then read using a spectrophotometer (Labsystems Multiskan plus) 
at 595nm. If the samples were highly concentrated, then a 1:10 or 1:20 dilution of the 
sample was prepared as required. 
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2.2.4. 1-D Electrophoresis 
Equal amounts of protein were loaded on to SDS-PAGE minigels along with loading 
buffer. Resolving gel strengths used were 12% (Occludin analysis), 7.5% (Zo-1) and 
14% (claudins). Resolving gel recipes are given in Table 3.1 
 
After the resolving gel had set, the butanol was poured off. The resolving gel 
was then topped with stacking gel with a Teflon comb was placed into the gel. The 
gel was allowed to set. The gel rigs were filled with 1x running buffer. The rubber 
lining was removed from the plates after the gel had set. The plates were then gently 
placed into the rigs, avoiding any bubbles from forming under the gel. 
 
The gap between glass plates in the gel rig was then filled with 1x running 
buffer to immerse the gels completely in buffer. 30ug protein sample was added to 
10µl of 4x sample buffer. The protein samples were then boiled for 3 minutes. Equal 
amounts of protein per sample were loaded on to each well after loading 5µl of the 
molecular weight marker in the first well. The electrophoresis was then run at 150V 
and 100mA for 1.5 hours (or 2 hours for Zo-1). When the dye from the loading buffer 
reached the bottom of the gel, the electrophoresis was stopped and the plates 
removed. The stacking gel was cut and removed from the gel. 
 
2.2.5. Western Blotting Protocol 
The Bio-Rad semi-dry electroblot apparatus was prepared by placing 2 sheets 
of blotting paper, cut to the size of the gel and soaked in transfer buffer, on the 
ceramic transfer platform. One sheet of nitrocellulose membrane cut to the exact size 
of the gel, was placed on top of the wet blotting paper followed by the resolving gel 
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and two further sheets of blotting paper (also soaked in transfer buffer). The lid was 
placed on top of this and securely closed. The electroblot was run at a current of 
0.9mA per gel for 1.5 hours (3.0 hours for Zo-1). The proteins should move from the 
gel to the nitrocellulose membrane due to the negative charge imparted by SDS. They 
are attracted towards the positively charged nitrocellulose membrane.  
 
After transfer, the membrane is briefly rinsed in TBS. Efficiency of transfer was 
determined using Ponceau S solution (Sigma Aldrich). The membrane was rinsed 
again to wash off the Ponceau S dye. It was then incubated in a blocking solution of 
5% (w/v) Bovine Serum Albumin (BSA) in TBS for one hour at room temperature on 
the shaker. After incubation, the membrane was rinsed briefly with TBS and 
incubated in blocking solution containing a 1:5000 dilution of the antibody for the 
protein of interest. The membrane was incubated at 4oC overnight on the shaker. 
 
Post incubation, the blocking solution containing the antibody was removed and 
stored at 4oC for re-use. The membrane was washed thrice for 5 minute in TBS 
containing 0.2% (v/v) Tween-20. It was then re-incubated in blocking solution 
containing a 1:5000 dilution of the secondary antibody for 3.0 hours at room 
temperature. The secondary antibody used was species-specific IgG conjugated with 
horse radish peroxidase (HRP) or alkaline phosphatase (AP). The diluted antibody 
was removed and stored at 4oC for reuse. The membrane was washed 3x in TBS 
containing 0.2% (v/v) Tween-20 for 5 minutes. 
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2.2.5.1. Chromogenic detection 
Chromogenic detection of protein was done using the Invitrogen Western-breeze 
Chromogenic kit – (anti-mouse). Membrane blocking and wash steps were carried out 
as per instructions in the manual. The membrane was incubated overnight with the 
primary antibody at 4oC on a shaking platform. It was then washed 3x in diluted wash 
buffer provided with the kit and then incubated with alkaline phosphatase-conjugated 
mouse anti-IgG at a concentration of 1:5000 for 2.0 hours at room temperature. The 
blot was rinsed post incubation and developed using the chromogenic substrate 
provided with the kit. The developed blot was scanned and densitometric analysis 
performed using Alpha Imager FC. 
 
2.2.5.2. Enhanced Chemiluminescence 
Post-transfer, the nitrocellulose membrane was incubated in a blocking solution [5% 
(w/v) BSA in TBS] for 2.0 hours. Membranes were washed quickly in TBS and 
incubated with the polyclonal rabbit anti-claudin2 or anti-claudin3 antibodies 
(1:5000) overnight at 4oC. The membranes were washed 3 times with 0.1% (v/v) 
Tween20 in TBS and incubated with secondary anti-rabbit IgG with HRP-conjugate 
(1:5000) for 3.0 hours at room temperature. Immune complexes were detected using 
enhanced chemiluminescence. The film was scanned and densitometric analysis 
performed using Alpha Imager FC software. 
 
2.2.5.3 Densitometric analysis 
The finished blot was placed over the platform inside Alpha Imager under white light 
only option. The blot was positioned to get a clear view for the camera and the focus 
was adjusted using Imaxia Gelfox software. A photograph was taken and the image 
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was saved in tiff format. The protein bands on the blot was selected using Gelfox and 
the total pixel density per band was calculated and saved to file. 
Experiments were performed in duplicates or triplicates. Mean density of all repeats 
were used for statistical analysis. 
 
2.2.6. Viability Assay: 
ARPE-19 cells were propagated in 6-well cell culture plates in 10% (v/v) growth 
medium, until confluent.  The medium was changed to the serum-free composition, 6 
hours prior to growth factor treatment. Cells were incubated for 24 hours with growth 
factors as described earlier. The culture was then washed 3 times with PBS and 
trypsinized by adding 200µl of 0.25% (v/v) Trypsin-EDTA solution. Trypsinisation 
was stopped by adding 200µl of complete medium. A 20µl aliquot was removed from 
this and an equal volume of 0.4% (w/v) Trypan Blue (Sigma Aldrich) was added. This 
was allowed to stand for 5 minutes. Cell suspension (10µl) mixed with Trypan blue 
was applied to a haemocytometer, and the ratio of viable to non-viable cells 
determined. The plasma membranes of non-viable cells are permeable to Trypan blue 
and hence take up the dye and appear blue while observed under the microscope 
 
2.2.7. Statistical analysis 
Statistical analysis of data obtained was done using single parametric Analysis of 
Variations (ANOVA) method. The data was compared and a P value <= 0.05 at 95% 
accuracy was considered statistically significant. A minimum of two sets of values 
were used for comparison of results. 
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2.2.8. Immunofluorescence 
Cells grown to confluence in T25 flasks were washed 3 times with sterile PBS to 
remove any traces of serum, followed by trypsinization and centrifugation. The pellet 
was dissolved in 1.0 ml of fresh medium. Sterile 1cm2 coverslips were placed in 6 
well tissue culture plates and 100µl of cell suspension aseptically placed on top. The 
plates were then incubated at 37oC for 2.0 hours to allow the cells to settle. After 2.0 
hours, 2 ml of 10% (v/v) complete medium was added to each well, and the cells were 
reincubated at 37oC until the desired degree of confluence was achieved. Coverslip-
immobilized cells were treated with growth factors as explained previously. The 
treated cells were then washed 3 times in sterile PBS and fixed for 10minutes in ice-
cold methanol. The methanol was then aspirated to waste and the cells washed 
quickly in 2.0 ml PBS to avoid drying. 
 
The coverslips were then blocked in 3% (w/v) BSA in PBS for one hour at room 
temperature. Following this, the cells were rinsed briefly with PBS and incubated with 
the primary antibody at 4oC overnight. After incubation, the cells were washed 3 
times with PBS for 10 minutes each. The cells were then incubated with the 
appropriate biotinylated secondary antibody for 2.0 hours at room temperature. The 
cells were washed again with PBS. They were then incubated with 1:200 dilution of 
flourescein streptavidin (Vector Labs) for 15 minutes in the dark. Following a further 
wash with PBS, the coverslips were mounted on a glass slide using a fluorescence 
mounting medium containing DAPI (Vector Labs). The cells were then observed 
under the flourescence microscope and images captured using CellTM software. 
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2.2.9. Immunohistochemistry (IHC) 
2.2.9.1. Tissue Rehydration 
Paraffin-embedded tissue sections were gifted by Dr. Helen Lambkin. The tissue 
specimens were cut into 5.0 µM sections using a microtome and mounted on silanized 
charged slides. They were allowed to dry for 15 minutes, followed by one hour 
incubation at 58oC.  
 
2.2.9.2. Dewaxing and antigen retrieval 
The slides were submerged in two changes of xylene (5 min), followed by two 
changes of absolute alcohol (5 min). The slides were then submerged in spirit for 1 
minute followed by rinsing with tap water for 2 minutes to remove the alcohol. The 
slides were then allowed to sit in citrate buffer preheated to 95oC for 45 minutes. They 
were then treated with 3% (v/v) methyl hydrogen peroxide for 5 minutes to inactivate 
endogenous peroxidases. 
 
2.2.9.3. ABC staining method 
The ABC staining was done using a Vectastain kit as per manufacturer’s instructions. 
The slides were washed in PBS (5 min), blocked using Normal Horse Serum (10 min) 
and then washed again with PBS (1 min). They were then incubated in the primary 
antibody for either 2 hours at room temperature or 4oC overnight. The slides were 
then washed three times with PBS (5 min) and secondary antibody added and 
incubated for 1 hour.  The sections were washed thrice with PBS (5 min) and then the 
ABC peroxidase (Vector Labs) was added and incubated for 15 minutes. After the 
wash step, the slides were incubated in DAB peroxidase (10 min). When sufficient 
colour had developed, the slides were washed using tap water and counter-stained 
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using Meyer’s Haematoxylin for 1 minute. They were then blued in warm running 
water for a minute. 
 
2.2.9.4. Rehydration 
Slides were rehydrated by immersion in spirit for 1 minute, followed by two changes 
of absolute alcohol for 3 and 10 minutes respectively. They were then submerged in 
xylene (5 min) followed by a second change of xylene (2 min). DPX was added and a 
coverslip applied. 
 
2.2.10 2-D Electrophoresis 
2.2.10.1. Acetone precipitation 
Samples were extracted using extraction buffer as described in section 2.2.2. A 
specific volume of test sample containing approximately 500µg protein was pipetted 
into a 1 ml tube and diluted five-fold with ice cold acetone. This was then mixed by 
vortexing and left at -20oC for 2.0 hours. The sample was then removed and spun at 
10000 rpm for 20 minutes at 4oC. The acetone was aspirated to waste and the protein 
pellet dried at room temperature. 
 
2.2.10.2 IPG Strip rehydration 
IPG strips in the pI range pH 3-10 were used. A 2.5ml aliquot of rehydration stock 
solution was slowly thawed at 4oC prior to use. IPG buffer (12.5µl) and DTT (7mg) 
was added per 2.5ml of rehydration solution. The solution was inverted slowly and 
250µl aliquots added to each protein pellet. Proteins were dissolved by gently mixing 
for 15 minutes at room temperature. 
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The protective lid was removed from the re-swelling tray and 250µl of re-hydration 
solution containing the protein pellet was pipetted into the central point of each tray 
slot. The protective foil cover lining the IPG strip was gently removed, starting at the 
acidic end marked (+). Each strip was gently laid down on the solution, with the gel 
side facing down. The strip was gently lifted and lowered back-and-forth so that the 
fluid covered the entire strip. Care was taken to avoid air bubbles forming in the 
solution. The strips were then covered with 2 ml of dry strip cover fluid to prevent 
evaporation. The re-swelling tray lid was replaced and the strips allowed to hydrate 
overnight at room temperature. 
 
2.2.10.3 Isoelectric focusing (IEF) 
The ceramic manifold was placed on the Ettan IPGphor Isoelectric focusing system 
platform. Drystrip cover fluid was added to each of the manifold channels. The 
hydrated strips were gently removed and placed, gel-side-up, on filter paper to remove 
excess cover fluid. The strips were then placed gel-side-up on the manifold, with the 
anode (+) end aligned with the 13cm mark on the IEF platform. An appropriate 
number of paper wicks were counted and 150µl of double distilled water added to 
each wick. A wick was placed at each end of the strip in such a way that one end of 
the strip overlapped the end of the gel. The electrodes were placed on top of all wicks, 
ensuring that the electrodes were in contact with the wicks, and the electrode cams 
were swivelled into closed position. 
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The IPGphor lid was programmed with parameters shown in table below and the lid 
was closed. 
Voltage -mode Voltage Volt-hours Duration (hours) 
Step and hold 500 500 1 
Step and hold 1000 1000 1 
Step and hold 8000 14500 2 
 4 
 
2.2.10.4 IPG strip equilibration 
Following IEF, the IPG strips were taken from the manifold and placed on a filter 
paper to remove excess cover fluid. The SDS equilibration solution was thawed at 4oC 
and 10ml added to a clean test tube. DTT was then added to this just before use. IPG 
strips were gently placed into these test tubes with the support film towards the wall. 
The test tube mouth was closed using Parafilm® and placed on Spiramix rotating 
mixer for 15 minutes. Equilibration saturates the IPG strips with the SDS buffer 
system required for the second dimension separation of proteins. 
 
2.2.10.5. Electrophoresis 
Buffers and reagents were prepared as previously described (Section 2.3). A 12% 
SDS PAGE gel was prepared as previously described in section 2.1.4.2. Resolving gel 
was poured between plates, leaving approximately 0.5cm gap from the top. A layer of 
butanol was added to ensure a level surface for the gel. The resolving gel was allowed 
to set for 30 minutes. Butanol was poured off after the gel had set and excess butanol 
was rinsed off with distilled water. The IPG strip was removed from the equilibration 
solution and rinsed carefully in running buffer. It was then placed carefully on top of 
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the SDS-PAGE gel, face-side-up, with the plastic side in contact with the glass plate. 
The gel was then pushed down gently with a forceps until the strip was in contact with 
the gel. Care was taken to ensure that no air bubbles were present between contact 
surfaces. A small plastic spacer was placed beside the strip, and 1% agarose poured 
into the glass plates to hold the strip in place during electrophoresis. The plastic 
spacer was removed after the agarose had set, leaving a well for applying the 
molecular weight marker. 
 
The gel was run at 150V per gel for 3.5 hours. At the end of this run, the bromophenol 
blue dye had reached the bottom of the gel. The gel was then removed from the glass 
chamber and the IPG strip and agarose discarded. 
 
2.2.10.6 – Coomassie blue staining 
 The gel was placed on plastic trays and a sufficient volume of Coomassie blue stain 
was poured to cover the gel. The tray was placed on a shaker and the gel was stained 
using Coomassie brilliant blue overnight. The stain was discarded and the gel was 
then destained in destain-1 for 1.0 hour followed by destain-2 overnight or until the 
background was clear. The destained gels were scanned using a scanner for further 
analysis. The optimized time scale for 2-D electrophoresis is provided in the table 2.3  
below, as used in all subsequent experiments. 
Step Temperature Time 
Day 1 
Protein sample (1000µg) + 4x Acetone Incubation -20C 2 hours 
Centrifuge – 10,000 rpm 4C 10 min 
Pipette off Acetone. Airdry Room temp 5 min 
Heat Samples 100C 3 min 
Cool on bench Room temp 5 min 
Add 250ul rehydration stock (DTT+Buffer) per 
pellet 
- 5 min 
Mix Room temp 15 min 
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Place on reswelling tray. Add IPG strip face down. 
Cover with oil and allow to rehydrate 
Room temp 8-12 hours 
 
Step Temperature Time 
Day 2 
Set Manifold on IEF. Cover with oil - 5 min 
Transfer strips to manifold - 20 min 
Place wet paperwicks on both sides of gel - 20 min 
Place electrode cams. Lock into position - 10 min 
Run IEF Room temp 4-5 hours 
 
Step Temperature Time 
Day 3 
Blot excess oil from gel - 5 min 
Equilibrate gel in Equilibration solution - 20 min 
Prepare resolving gel (leave 0.5cm space) - 30 min 
Resolving gel set time - 30 min 
Add IPG strip to resolving gel - 10 min 
Add 1% agarose (+bromophenol blue)  – Allow to 
set 
- 5 min 
Setup SDS system. Add m.w marker - 10 min 
Run 2D - 4-5 hours 
 
Step Temperature Time 
Day4 
Transfer gel to Coomassie blue - 30 min 
Stain - 8-12 hours 
 
Step Temperature Time 
Day 5 
Destain 1 Room temp 1-1.5 hour 
Destain 2 Room temp 8-12 hours 
Table 2.3: Optimized time scale for 2 dimensional electrophoresis of RPE samples. 
Processing time from sample preparation until the stage of obtaining the final destained gel 
was five days. 
 
2.2.10.7 – Silver Staining 
Silver staining and destaining was done using ProteoSilver kit (Sigma Aldrich) as per 
manufacturer’s instructions. All steps require constant agitation and hence were 
performed at room temperature on a shaker. The steps are outlined below. 
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a) Fixation 
The gel was fixed in a solution containing 50% (v/v) ethanol and 10% (v/v) acetic 
acid for 20 min., followed by 30% (v/v) ethanol for 10 minutes. The gel was then 
washed in distilled water (10 min.). 
 
b) Sensitisation 
The gel was sensitized in sensitizing solution provided for 10 minutes. It was then 
washed twice in distilled water for 10 minutes each. 
 
c) Silver equilibration 
Silver solution was added to the gel for 10 minutes,  after which it was washed with 
water. 
 
d) Development 
Developer solution was added and the gel agitated until spots became visible. After 
the desired stain intensity had been achieved, colour development was halted by 
stopping solution, followed by washing (15 min.) and the result archived using a flat-
bed scanner. 
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Investigation of the effects of selected modulators on regulation of tight junction 
protein expression within this study was carried out by electrophoretic and 
cytochemical techniques, in conjunction with immuno-localization of target proteins. 
To permit reproducible comparative analysis of protein expression over the entire 
study period, it was necessary to perform standardization experiments to identify 
optimal assay conditions and to characterize the robustness of the detection methods. 
Variations in global protein expression in response to treatment challenges utilized 2-
dimensional gel electrophoresis, and this was complemented by SDS-PAGE and 
western blotting to study the expression of specific biomarkers. Bio-distribution 
studies to localize the expression of a selection of target biomarkers within cells 
utilized fluorescent-labelled antibodies.  
 
3.1 Two-Dimensional (2-D) Electrophoresis 
The technique of 2-D gel electrophoresis was selected to study the effect of growth 
factors on the RPE proteome, comparing the resultant fingerprint (generated on the 
basis of molecular mass and isoelectric point) with in-house data and previously 
published reports. An integral aspect of deploying this technique is ensuring adequate 
amounts of protein which can be reproducibly detected after separation in both 
dimensions. Using the method previously described by Brankin and colleagues 
(2006), it was found that it was only possible to reproducibly prepare cell 
homogenates with a maximum protein concentration of 0.8–1mg/ml; previous studies 
have also reported extensive protein loss at almost every stage of sample preparation 
and transfer (Zhou et al, 2005), citing proteolysis, the presence of unspecified 
contaminants or uncontrolled insolubilization of proteins as reasons. This loss of 
protein also contributes to experimental variations, reducing chances of reproducing 
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the 2-D gel pattern (Zhou et al., 2005). On the basis of such reports, and given that 
further optimization of homogenate preparation was beyond the scope of this work 
(on the grounds of limited time available), it was decided to try to compensate for this 
limitation by incorporation of a protein precipitation step into the sample preparation 
protocol, in conjunction with deployment of enhanced sensitivity detection 
methodology during the final band detection steps in the electrophoresis. 
 
Initial investigation of untreated RPE protein extracts by SDS-PAGE revealed densely 
staining bands in the regions of 30 kDa and 116 kDa (data not shown). Initial range-
finding experiments with the 2-D gel system revealed problems of run-to-run 
variation and a low number of (sometimes faintly stained) protein spots on gels (Fig 
3.1, a); the sub-optimal performance of the method was judged on the basis of 
comparison with previous in-house work on similar systems. A number of approaches 
were pursued to remedy this problem. 
 
Incorporation of an organic solvent (acetone) precipitation step into the sample 
preparation protocol allowed an approximate 50% increase in amounts of protein 
available for application to the gel, and thereby assuring that low abundance protein in 
the extract could be consistently detected. Additionally, the occurrence of streaks in 
the stained gel reduced the overall clarity and complicated the clear-cut interpretation 
of results. Such streaks have been variously attributed to the presence of membrane 
lipids, contaminants and non-specific oxidation of proteins (Luche et al., 2004.); 
however, in the present work, the inclusion of DTT in the equilibration and re-
swelling buffers was not wholly effective in preventing streaks. Substitution of re-
swelling buffer with DeStreak Rehydration Solution (pH 3-10), a product available 
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from GE Life Sciences (UK), was found to eliminate such artefacts (Fig 3.1, b). 
Information regarding the components of this buffer was not available from the 
company. However, it was successful in removing streaks caused by protein oxidation 
and presence of lipids in the gel. 
 
Further minor modifications to the protocol were also found to have a beneficial 
effect on the quality of the gel end product. While the molecular mass standards could 
be detected on the final 2-D gel without much difficulty after using the ‘standard’ IPG 
strip equilibration protocol (20 – 30 minutes), it was determined empirically that 
efficient diffusion of analyte samples into the second dimension required a longer pre-
equilibration duration of 45 minutes.  
 
Variations in gel quality could also arise from the handling of the IPG strips. 
Experience through trial-and-error indicated that the latter were best handled when 
they were still nearly frozen and used immediately after removing from -20oC storage. 
It was observed that an increase in temperature caused the gels to stick to the plastic 
strip and tear while the strip was being removed.  
 
 
 
 
 
 
 
 
_____________ Standardization of techniques for detection of protein expression 
 52 
 
A B 
 
 
Fig 3.1: Establishment of optimized separation and detection parameters for the 
untreated RPE proteome sample.  
a. 200 µg protein, standard extraction protocol, standard re-swelling buffer containing 
DTT;  
b. 500 µg protein, organic solvent precipitation of protein, DeStreak Rehydration 
buffer. The organic solvent precipitation step was performed by taking 200µg of RPE 
extract and addition of a 4x volume of chilled acetone. Precipitates were air dried and 
resolubilized in 250µl of rehydration stock by gentle mixing. The standard strip re-
swelling protocol consisted of rehydration in 7M urea, 2M thiourea, 15mM DTT and 
4% Triton X-100. Gels were stained using Coomassie Brilliant Blue. Electrophoresis 
parameters were as outlined in section 2.2.10 
Note: Gels shown in picture are not of the same sample 
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Attempts to further optimize the detection of protein spots on gels focused on 
replacing-supplementing Coomassie Brilliant Blue with more sensitive staining 
methods. The advantage of higher resolution detection of protein spots for a smaller 
amount of protein sample (150 µg) using a silver staining protocol were offset by 
increased background staining (Fig 3.2), with the latter limitation exacerbated by the 
practical difficulty of processing multiple gels simultaneously. 
 
 
Fig 3.2: Detection of protein complement of untreated RPE extract by 2-gel gel 
electrophoresis and silver staining.  
Protein present in initial sample - 150µg. Electrophoresis parameters were as outlined 
in section 2.2.10. Arrows indicate protein spots visible in final gel. Heavy background 
staining was obtained in the initial gels after destaining silver stained gel. Double 
staining partially rectified this problem and the gel obtained was much clearer. 
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The use of silver stain on gels, with subsequent staining in Coomassie Brilliant Blue, 
was also examined; such protocols have been reported to increase protein detection 
sensitivity on electrophoretic gels by up to eight-fold (Fernandez-Patron et al 1995; de 
Moreno et al, 1986; Irie et al 1982). Preliminary experiments indicated that the use of 
this technique may provide higher contrast preparations than the use of silver staining 
alone (Fig 3.3); indeed, removal of non-specific background staining was 
experienced, resulting in improved gel clarity. However, the relative convenience of 
the Coomassie blue method, in conjunction with the other assay improvements 
outlined above, dictated that it was the primary staining method used in this study. 
The final optimized 2-D gel electrophoresis protocol used in all subsequent 
experiments is described in Table 2.3, Section 2.2.10.6 of Materials & Methods.  
 
Analysis of changes in RPE proteome treated with VEGF using 2-D electrophoresis 
was attempted in the initial period of study. It is nearly impossible to study tight 
junction protein changes by the 2-D electrophoresis method, owing to a very low 
percentage of membrane proteins in the RPE proteome extract prepared for this 
analysis. The 2-D electrophoretic analysis may prove to be an excellent tool for 
studying pathological changes in the total RPE proteome and would be handy in 
identifying key protein biomarkers in diseased RPE. The focus of this project was to 
look at the modulation of RPE barrier function, involving changes in expression of 
key membrane proteins involved in formation of tight junctions. Hence this method 
was found inadequate. Also owing to time constraints in the project, this experiment 
was not continued. 
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Fig 3.3: Detection of protein complement of untreated RPE extract by 2-
dimensional gel electrophoresis. Gel was double stained using silver and 
Coomassie Brilliant Blue. 
Protein loading: 200µg. Electrophoresis parameters were as outlined in section 2.2.10 
 
 
 
 
200 kDa 
 
116 kDa 
97 kDa 
 
 
66 kDa 
 
55 kDa 
 
45 kDa 
 
 
36 kDa 
 
 
 
29 kDa 
 
 
 
 
 
24 kDa 
 
 
 
 
20 kDa 
 
 
14.2 
kDa 
_____________ Standardization of techniques for detection of protein expression 
 56 
 
3.2 Western Blotting 
The modulation of expression of specific RPE proteins in response to growth factors 
was assessed by western blotting. This approach involved the separation of proteins 
by SDS-PAGE, followed by transfer to a nitrocellulose membrane and probing with 
specific antibodies. Antibody-antigen reactions were then detected by enzyme-linked 
conjugates (alkaline phosphatase or horse radish peroxidase).  
 
Initial investigation of protein loading and staining performance on SDS-PAGE gels 
identified the required amount of protein per gel lane (gel not shown). The full 
complement of proteins capable of being visualized by this technique was apparent at 
a gel loading of 20µg of protein, without incurring serious lane distortion, and this 
was selected for subsequent use in western blotting experiments (Section 2.2.5). 
However, problems were encountered in transferring proteins from the gel to 
nitrocellulose using the dry cell blotter available in the laboratory. Attempts to effect 
consistent transfer of proteins using the standard current setting and recommended 
blotting times necessitated further optimization, and Beta actin was used as a loading 
control for this purpose.  
 
Problems with non-specific binding were also encountered. The Invitrogen Novex® 
Western Breeze™ Chromogenic kit (anti-mouse) kit was used as the standard 
immuno-staining tool for colourimetric analysis of protein of interest. However, the 
Hammerstein casein blocking solution provided with the kit was not found to be 
suitable in all situations. The use of Bovine Serum Albumin [BSA; 3.0% (w/v) in 
TBS] was necessitated when certain custom dilutions of antibodies were to be used. 
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The proteins were initially visualized using BCIP/NBT (5-bromo 4-chloro 3’-indoyl 
phosphate/nitro-blue tetrazolium). Early experiments performed according to the 
manufacturer’s instructions produced blots which suffered from high background 
staining, hampering the clear-cut interpretation of the protein bands (Fig 3.4 a). 
Further investigation of the problem indicated that the washing protocol was of key 
importance. Manufacturer’s instructions specified that blots be subjected to a washing 
regime involving 3 x 5 minutes. rinses (in 1:15 diluted wash buffer). However, when 
the duration of wash steps was increased to 10 minutes per wash, background staining 
was greatly reduced (Fig 3.4 b). 
 
a  b  
Fig 3.4: Influence of blot washing protocol on background staining.  
Beta actin was used as a loading-transfer control. The blot was developed for enzymatic 
staining using either the manufacturer’s washing protocol (5 minutes (a)) or the 
laboratory-derived method (b). The molecular markers were Precision Plus Protein™ 
WesternC™ standards (BioRad). Minigels were routinely used for western blot. Ponceau 
S was used to confirm protein transfer in advance of blot processing for antibody-enzyme 
staining. Arrows indicate beta actin band visible on the blot after development. 
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The next phase of the work involved further standardization of the system using 
representative RPE proteins (derived from treated/untreated cell preparations). Two 
tight junction proteins, of different molecular mass, were selected for this purpose: 
occludin, a 65kDa protein and Zo-1 with a molecular mass of 220kDa. A 
representative blot showing the staining of occludin is shown in Fig. 3.6. Optimal 
transfer times were found to be in the region of 2hours (occludin) to 3.5hours (Zo-1). 
 
 
 
    a    b     c       M 
 
Fig 3.5: Representative standardization blot for occludin. 
ARPE-19 cells were treated with VEGF and RPE proteins extracted as described in 
section 2.2.2. VEGF (ng/ml): A, 100; B, 10; C, 0; M, molecular weight markers. 
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Amplification of the antibody-binding reaction by chemiluminescence (Fig. 3.6) was 
also investigated as a detection tool as this method is more sensitive (Conrad et al, 
2001). The system used employed HRP-labelled secondary antibody and beta actin 
was initially used as a transfer control.  
 
 
Fig 3.6:  Principle of chemiluminescent visualization of proteins on western blot. 
(from MacPhee, 2010)  
 
For optimal detection of tight junction proteins, overnight incubation with primary 
antibody at 4oC on a shaker was followed as a rule, followed by incubation in 
secondary antibody at room temperature for 3 hours. Issues regarding the purity of 
commercially-sourced antibodies were identified as a vital factor in contributing to 
background staining. Tight junction antibodies bought from Invitrogen were the final 
choice after trying the product of a variety of other suppliers. 
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3.3 Immunoflourescence 
Growth factors which showed a significant effect on RPE protein expression (as 
detected by western blotting) were selected for further study to examine their 
expression within cells.  In the technique of immunofluorescence, antibodies are used 
directly on cultured, fixed cells, to probe for the expression of the tight junction 
protein of interest, thereby allowing direct visualization of its location in the cell.  
 
For imaging convenience, it was essential to grow the cells on a surface which could 
be used with a microscope. While chamber slides (Labtek) were available, they 
suffered from the disadvantage of being prone to contamination due to the loose top 
cover (and were also relatively expensive). The use of 0.1% (w/v) gelatine coated 
sterile coverslips proved to be a viable alternative, although slight background 
staining was evident during image capture (Fig 3.7a) as compared with a non-gelatine 
coated control slide (Fig 3.7b). RPE cells did not exhibit auto-fluorescence (data not 
shown) when tested for the same. 
 
Three different cells fixatives were investigated for optimal performance: acetone – 
formalin (1:1), formalin (3% v/v) and ice cold methanol. Of these, methanol was 
found to give superior results. Formalin fixation required an additional 
permeabilization step using Triton-X 100. Fixation using 100% methanol has been 
previously shown to preserve cell morphology (Nogouchi et al, 1997) and does not 
require additional permeabilization treatments. Hence this was the method of choice 
in the current study. The antibody staining protocol was initially tested using a 
vimentin antibody, which was found to work well using a 1:150 dilution (Fig 3.8).  
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a  b  
Fig 3.7: Gelatine coated slide: non-specific background staining using FITC label. 
A 0.1% Gelatin coated blank cover slip (a) and uncoated cover slip (b) were tested for 
background fluorescence. No cells were cultured on these slides. Experimental conditions 
were the same as that for cultured cover slips. Gelatin coating contributed to background 
fluorescence. 
 
 
 
 
Fig 3.8: FITC-stained RPE cells probed for vimentin.  
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Untreated RPE cells cultured on coverslip was probed using 1:500 dilution of 
vimentin antibody. The cells were stained with FITC. Images captured at 
magnification: x40 
Slightly more difficulty was encountered when using antibodies directed against tight 
junction proteins. Although Zo-1 presented little challenge, background staining was 
encountered with occludin antibody, compounded by the fact that it needed a longer 
incubation time to obtain satisfactory results. Indeed, achieving a balance between the 
antibody incubation duration required to effect detection of the target bio-molecule, 
and the avoidance of unacceptable background staining, was a recurring theme. For 
example, no staining was apparent if anti-claudin–1 was incubated at 4oC for up to 16 
hours. Extending the incubation duration to 24 hours at 4oC for the primary antibody 
produced a target-specific signal, but contributed to non-specific binding (result not 
shown). Such a situation was also encountered in the case of RPE cells probed for 
claudins 2, 3, 4 and 5: heavy background signal was accompanied by a granular 
staining pattern in the cytoplasm (Fig 3.9). Fortuitously, certain claudin antibodies 
were being used simultaneously by other workers in the laboratory, and the dilutions 
optimised by immuno-histochemistry using breast and cervical carcinoma tissues, 
were also found to be suitable for the present studies; remaining claudin antibodies 
(claudins 2, 3 and 4) were used at dilutions recommended by the manufacturer, and 
provided adequate results. A representative set of images of RPE cells stained for 
Occludin and Zo-1 are shown in Fig 3.10. 
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Fig 3.9: RPE cells stained for expression of Claudin-1 
Untreated RPE cells cultured on coverslip probed using for claudin-1. Incubation time 
–16 hours. Texas Red staining shows granular cytoplasmic staining pattern; nuclei 
stained using DAPI. Magnification x40. 
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a) 
 
b) 
 
c) 
 
 
Fig 3.10: Untreated RPE cells probed for (a) occludin, (b, c) Zo-1. (Optimized) 
Incubation time used – 12 hours. The cells were stained using FITC. Nuclei stained 
using DAPI in b and c. Magnification x40, except c (x10). 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 4 
 
Effect of Growth Factors on the outer 
Blood Retinal Barrier 
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4.1. Introduction 
Vascular endothelial growth factor is the collective name for a family of pro-
angiogenic growth factors. VEGFs are primarily involved in development and 
differentiation of vascular endothelium and promote neovascularisation. VEGF has 
been identified as a key protein involved in the breakdown of the BRB. However, the 
molecular mechanism of this has to be further elucidated. 
 
4.1.1 VEGF structure and functions 
Vascular endothelial growth factors belong to the VEGF / PDGF (Platelet Derived 
Growth Factor) group of the cysteine knot super-family of hormones and growth 
factors (Holmes and Zachary, 2005). The VEGF family consists of a group of 
structurally and functionally related pro-angiogenic growth factors named VEGF-A, 
VEGF-B, VEGF-C, VEGF-D, VEGF-E, VEGF-F and Placental growth factor (PlGF). 
Of these, VEGF-A, B, C, D and PlGF are expressed in humans (Holmes and Zachary, 
2005). VEGF-A is the most thoroughly studied among the VEGF family and has nine 
isoforms produced by alternative splicing of a single VEGF gene consisting of eight 
exons (Bhishitkul, 2006). These isoforms are named on the basis of the number of 
amino acids present in their sequence as indicated by the subscript number. Currently 
identified isoforms of VEGF-A are VEGF121, VEGF145, VEGF148, VEGF162, 
VEGF165, VEGF165b, VEGF183, VEGF189 and VEGF206 (Shams and Ianchulev, 2006).  
 
Studies conducted by Hartnett et al., 2003 showed that co-culture of RPE cells with 
endothelial cells reduced the barrier properties of the RPE and the reduction was in 
part mediated by soluble VEGF. The same study reported greater release of soluble 
VEGF into the medium compared to solo culture of RPE. VEGF and cytokines 
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including TNF-α have been shown to disrupt RPE barrier function (Ablonczy and 
Crosson 2007, Hartnett et al 2003) and to cause a reduction in regulated removal of 
subretinal fluid, leading to macular oedema (Funatsu et al 2009, Ablonczy and 
Crosson 2007). Patients suffering from Proliferative Diabetic Retinopathy (PDR) 
were reported to have a very high level of VEGF (5.42ng/ml) as compared to a non-
diabetic subject (9pg/ml) (Funatsu et al, 2005, Mitamura et al, 2002). However, the 
exact molecular mechanism that leads to growth-factor-mediated disruption of oBRB 
has not been elucidated. 
 
The biological effects of VEGF are mediated through a family of tyrosine kinase 
receptors known as VEGF Receptors (VEGFRs) (Holmes and Zachary, 2005). The 
VEGFRs differ considerably in their signalling properties and are assisted by non-
signalling co-receptors in the signalling cascade. VEGFR-1 and VEGFR-2 play a key 
role in angiogenesis of blood vessels while VEGFR-3 is associated with 
lymphangiogenesis. Fig 4.1 shows the association of various isoforms with VEGFRs. 
 
Fig: 4.1 – VEGF - VEGFR interaction (Source: Hicklin and Ellis, 2005) 
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4.1.2 Placental Growth Factor 
PlGF is a 38kDa, pro-angiogenic member of the VEGF family and shares several 
functional traits of other VEGF isoforms. As the name indicates, PlGF is expressed in 
placental cells and is primarily involved in embryonic vasculogenesis. However, PlGF 
is also produced by non-placental cells including RPE (Miyamoto et al 2008). 
 
PlGF occurs as a homodimer and shares substantial structural similarity with VEGF-
A (Miyamoto et al, 2008). Four PlGF isoforms are produced by alternative splicing of 
the PlGF gene (Yang et al 2003). PlGF isoforms do not interact with VEGFR2, but 
selectively bind to the VEGFR-1 receptor. PlGF is produced by RPE under hypoxic 
conditions (Hollborn et al 2006). Patients suffering from PDR were reported to have 
very high levels of PlGF of up to 1.039ng/ml (Mitamura et al, 2002). PlGF is found in 
very low levels of between 7pg/ml to 12pg/ml in the vitreous fluid of control non-
diabetic patients (Mitamura Y et al 2002).  
 
4.2. Aims 
VEGF and PlGF are key proteins that cause breakdown of iBRB. The RPE has been 
found to produce VEGF and PlGF directly (Kaur et al. 2008, Kannan et al. 2006, 
Strauss 2005). Hollborn et al, (2006) reported that unstimulated RPE secretes between 
100 to 250pg/ml VEGF into the medium (Hollborn et al, 2006). However, the effect 
of PlGF and VEGF on the Retinal Pigment Epithelial barrier has not been extensively 
investigated. In this study, it was therefore of interest to examine the latter aspect. The 
expression and localization of occludin and Zo-1 on RPE membrane was studied 
using western blotting and immunoflourescence staining. The toxicity of growth 
factors used was investigated using a standard Trypan blue assay. 
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4.3. Cell Culture and Growth Factor Treatment 
ARPE-19 cells were cultured as described in section 2.2.1 until desired confluence 
was achieved. The cells were then washed thrice to remove all traces of serum and 
incubated in serum-free medium for 6 hours. Afterwards, the monolayer was rinsed 
with sterile PBS and treated with 10-100ng/ml VEGF or 1-10ng/ml PlGF for 24 
hours. Following treatment, the cell monolayer was rinsed with sterile PBS to remove 
any traces of medium. The cells were then extracted as described in section 2.2.2. 
Protein analysis of the cell extract was performed using the Bradford assay as 
described in section 2.2.3.  
 
Equal amounts of protein per sample were loaded to minigels. Electrophoresis was 
performed as described in section 2.2.4. The separated proteins were then blotted to a 
nitrocellulose membrane using the optimized method described in 2.2.5. Transfer time 
used was 2 hours for Occludin and 3.5 hours for Zo-1. 
 
Cell viability assay was performed using trypan blue (Sigma Aldrich) as described in 
section 2.2.6 
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4.4 Results and Discussion 
4.4.1 Occludin expression in VEGF treated RPE 
In this study, changes in tight junction expression were observed in cultured RPE cells 
exposed to different concentrations of VEGF or PlGF for a 24 hour period. 
 
Analysis of VEGF-mediated protein expression by western blot (Fig 4.2) yielded 
inconclusive results; an apparent down-regulation in expression of occludin in RPE 
treated with VEGF was evident (Fig 4.3), but this was not statistically significant (P> 
0.05) when subjected to densitometric analysis using Imaxia Gelfox (Table 4.1). 
Parametric analysis was done using ANOVA 
 
 
Fig: 4.2 – Western blot analysis of effect of VEGF on occludin in RPE.  
The blot was developed using chromogenic substrate BCIP/NBT. Normalisation of 
blots was achieved using beta actin. Blot was done in duplicate. 
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VEGF 
concentration Mean P Value 
0ng/ml 7557 
10ng/ml 6443.5 
100ng/ml 5597.5 
0.366 
 
Table 4.1 Mean pixel intensities for two sets of samples shows a decrease in occludin 
band intensity with exposure to VEGF. P-value calculated using single factor ANOVA 
shows that the change is not statistically significant. 
Effect of VEGF occludin expression in RPE
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Fig: 4.3 Effect of occludin expression in RPE cells treated with VEGF.  
Occludin in RPE is down-regulated with exposure to VEGF. The graph represents the 
mean value for two western blot analyses and the standard error of the mean is represented 
by Y-error bars. 
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However, investigation of cellular occludin expression by immunoflourescence 
imaging confirmed a reduction in occludin production, evident by a loss of junctional 
staining in RPE cells, after exposure to 1.0 and 10ng/ml VEGF (Fig 4.4). Such 
concentrations of VEGF are representative of in vivo levels associated with the 
disease state. For example, vitreous VEGF in a diabetic patient was found to be 
elevated as high as 5.424ng/ml, while in a healthy individual, it is 9.0pg/ml 
(Mitamura et al 2002). 
 
Increased paracellular permeability of RPE cells following exposure to high 
concentrations of VEGF has been reported previously (Ablonczy and Crosson 2007; 
Geisen et al 2006), and is recognised as an early sign of macular oedema and oBRB 
breakdown (Ablonczy and Crosson 2007; Caldwell et al 2005). However, 
Ghassemifar and colleagues (2006) reported that VEGF increased the TEER of 
ARPE-19 cells, and tightened the RPE junction. Such contradictory results reflect the 
complexity of the cellular control mechanism RPE function and point to the need for 
further studies in this area. 
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a) 
  
b) 
  
c) 
   
Fig: 4.4 Immunoflourescence staining showing junctional loss of occludin in 
cultured RPE cells treated with VEGF Untreated (a), treated with 10ng/ml (b) and 
100ng/ml VEGF(c). RPE cells were stained using FITC and images captured at 40x 
magnification. 
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4.4.2. Zo-1 expression in RPE treated with VEGF 
Expression of ZO-1 in RPE was not found to vary significantly following treatment 
with VEGF, as determined by western blotting (Fig 4.5). Densitometric analysis of 
band intensities indicated a progressive increase in expression of Zo-1 in VEGF 
treated RPE, although this was not statistically significant as evident from Table 4.2 
 
 
 
Fig: 4.5 - Western blot analysis of effect of VEGF on Zo-1 in RPE.  
The blot was developed using chromogenic substrate BCIP/NBT. Normalisation of 
blots was achieved using beta actin. Blot was done in triplicate. 
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VEGF 
concentration Band intensity (Mean ±SEM) P Value 
0ng/ml 4422.33 ± 907.4 
10ng/ml 6205.67 ± 1323.6 
100ng/ml 7219 ± 1060.3 
0.273 
 
Table 4.2 Mean band intensities (± standard error of mean) for three sets of samples 
treated with VEGF shows an increase in Zo-1 band intensity with exposure to VEGF. P-
value calculated using ANOVA shows that this change is not statistically significant. 
Effect of VEGF on Zo-1 expression in RPE
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Fig: 4.6 Effect of Zo-1 expression in RPE cells treated with VEGF.  
Zo-1 in RPE is up-regulated with exposure to VEGF. The graph represents the mean value 
for three sets of data and the standard error is represented by Y-error bars. 
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Investigation of Zo-1 expression in RPE using immunoflourescence staining showed 
de-localization of Zo-1 from membrane after treatment with 1.0ng/ml and 10.0ng/ml 
VEGF (Fig 4.7). 
 
Zo-1 is a member of the MAGUK family of proteins and interacts with occludin and 
claudins to maintain integrity of the barrier (Balda et al, 2003). Thus VEGF may 
affect barrier function by modulating Zo-1 levels, which may affect Zo-1 interaction 
with occludin and the claudin tight junction proteins. Additional factors to consider in 
future experiments would be to compare apical versus basolateral administration of 
VEGF, expression of VEGFR1 and VEGFR2 and effects on TEER. This additional 
data would allow us to predict more fully the effects of VEGF on RPE barrier 
properties, and on the outer BRB in vivo. 
 
Cultured ARPE cells have been reported to express very high levels of VEGF of upto 
777.2pg/ml in media, constitutively (Geisen et al, 2006). Basal administration of upto 
500ng/ml VEGF did not produce significant change in permeability in the RPE while 
apical administration of upto 1ng/ml produced a significant increase in permeability. 
Our data shows about 20% decrease in occludin expression in the RPE treated with 
100ng/ml VEGF as compared to the untreated sample. Although this value is not 
statistically significant (P>0.05), this is in agreement with studies mentioned earlier 
(Ablonczy and Crosson 2007, Geisen et al 2006). 
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a)  
 
b)  
 
c)  
 
Fig: 4.7 Immunoflourescence staining showing junctional loss of Zo-1 in cultured 
RPE cells treated with VEGF: Untreated (a), treated with 10ng/ml (b) and 100ng/ml 
VEGF(c). RPE cells were stained using FITC and images captured at 40x 
magnification. 
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4.4.3. Occludin expression in RPE treated with PlGF 
VEGF and PlGF belong to the same family of pro-angiogenic growth factors and 
shares significant similarity in their amino acid sequence (Holmes and Zachary, 
2005). Unstimulated ARPE cells secrete ~5ng/ml PlGF in vitro (Hollborn et al 2006). 
This is close to the level found in a normal vitreous fluid reported by Mitamura et al 
(2002).  
 
Western blot analysis of PlGF induced occludin expression (Fig 4.8) showed an 
increase in protein expression. Statistical analysis of mean occludin band intensities 
showed a progressive increase in protein expression (Fig 4.9). However, the two 
tailed P-values indicated that this change was not statistically significant (Table 4.3) 
 
 
Fig: 4.8 - Western blot analysis of effect of PlGF on occludin in RPE.  
The blot was developed using chromogenic substrate BCIP/NBT. Normalisation of 
blots was achieved using beta actin. Blot was done in triplicate. 
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PlGF 
concentration Band intensity (Mean ±SEM) P Value 
0ng/ml 2059.67 ± 247.1 
10ng/ml 2606 ± 224.5 
100ng/ml 3996.67 ± 554.8 
0.0259 
 
Table 4.3 The table shows mean occludin band intensities (± standard error of mean) for 
three sets of samples treated with VEGF. The data was compared and a P value ≤0.05 in a 
single parametric ANOVA was considered statistically significant. 
PlGF upregulates occludin expression in RPE
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Fig: 4.9 Effect of occludin expression in RPE cells treated with PlGF.  
Occludin in RPE is up-regulated with exposure to PlGF. The graph represents the mean 
value for three sets of data and the standard error is represented by Y-error bars. 
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Immunoflourescent staining showed a loss of junctional staining for occludin when 
cells were treated with PlGF (Fig 4.10). A study using FACS analysis could be 
performed in the future, whereby occludin expression on PLGF-treated and control 
RPE are quantitated 
a) 
 
 
b) 
  
Fig: 4.10 Immunoflourescence staining showing junctional loss of occludin in 
cultured RPE cells treated with PlGF: Untreated (a) and treated with 10ng/ml (b) 
PlGF. RPE cells were stained using FITC and images captured at 40x magnification. 
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PlGF levels as high as 1.034ng/ml was reported in the vitreous fluid of patients 
suffering from PDR (Mitamura et al, 2002). Elevated vitreous PlGF of up to 
806.5pg/ml was reported in patients suffering from PDR with macular oedema and 
may contribute to retinal oedema and accumulation of sub-retinal fluid in diabetic 
retinopathy (Miyamoto et al 2007). Intra-vitreous PlGF level in a healthy individual is 
reported to be between 7 – 12 pg/ml. In diabetic patients, the vitreous levels were 
found to be elevated to 100-1000pg/ml (Mitamura et al 2002). 
 
Although PlGF was expected to increase the paracellular permeability in RPE, it was 
seen to upregulate the occludin content in RPE, indicating possible strengthening of 
tight junctions. PlGF acts purely through VEGFR-1. VEGFR-1 activation stimulates 
expression of Pigment Epithelium derived factor (PEDF) which is a potent antagonist 
to VEGF and PlGF (Ohno-Matsui et al 2003). PEDF reverses redistribution of 
occludin from tight junctions caused by VEGF and PlGF (Ho et al 2006, Ablonczy et 
al 2009). Immunofluorescence images showed occludin localization at the RPE 
membranes (Fig 4.10).  PEDF was also found to upregulate occludin in retina of 
diabetic rats (Yu et al 2010). This antagonistic effect of PEDF may be the reason for 
up-regulation of occludin in PlGF-treated RPE cells as observed from western 
blotting. 
 
PlGF has been reported to produce no significant changes in permeability of the RPE 
(Ablonczy and Crosson 2007) although it has been found in elevated levels along with 
VEGF in patients suffering from diabetes (Miyamoto et al 2008, Mitamura et al 
2002). A recent study reports that prolonged exposure to PlGF leads to BRB 
breakdown (Kowalczuk et al, 2011). Immunoflourescence staining of occludin in 
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PlGF treated RPE showed change in membrane localization of occludin (Fig 4.10). 
This study involved a standard growth factor exposure time of 24 hours. By far, 
results reported regarding behaviour of PlGF in the retina are contradictory and 
further studies are warranted. A time dependant study of changes in barrier function 
may be useful in studying this further.  
 
Viability data obtained from trypan blue assay (Fig 4.11) showed that RPE cells 
retained 100% viability after exposure to 100ng/ml VEGF or PlGF. 
 
4.5 Viability Assay 
RPE cells were treated with 1ng/ml and 10ng/ml PlGF and 10ng/ml and 100ng/ml 
VEGF as described in section 2.2.2. Cell viability assay was performed as per 
protocol outlined in 2.2.6. 
 
a) VEGF 
A total of 98 cells were counted in 4 chambers of haemocytometer under microscope. 
All cells were unstained after exposure to trypan blue for 5 minutes. 
 
b) PlGF 
A total of 103 cells were counted in 4 chambers of the haemocytometer under 
microscope. All cells were unstained after exposure to trypan blue for 5 minutes. 
 
 
 
 
________________ Effect of Growth Factors on the Outer Blood Retinal Barrier 
 82 
 
 
 
 
 
Fig 4.11 - Percentage viability of cells treated with PlGF / VEGF for 24 hours.  
 
Cell viability assay performed on RPE cells showed that RPE cells retained viability 
after stepping down medium to serum free media for 6 hours followed by growth 
factor treatment for 24 hours (Fig 4.11).  
Cell viability assay PlGF vs VEGF
0
20
40
60
80
100
120
1ng/ml 10ng/ml 100ng/ml
Growth Factor concentration
Pe
rc
en
ta
ge
 
v
ia
bi
lit
y
PlGF
VEGF
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 5 
 
Effect of Cytokines on the outer Blood 
Retinal Barrier 
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5.1 Introduction 
An intact tight junction barrier is crucial for maintenance of retinal homeostasis. 
Pathogenesis and progression of several disorders involving breakdown of tight 
junctions are mediated by cytokines (Capaldo and Nusrat, 2009, Harada et al. 2006). 
RPE cells play an important role in the immune response. For instance, they express 
Major Histocompatibility complex (MHC) molecules, adhesion molecules, FasL and 
cytokines (Holtkamp et al, 2001). Cytokines such as Tumor necrosis factor alpha 
(TNF–α), Interleukin-1 beta (IL-1β) and Interferon-gamma (IFN-γ) regulate cells and 
also express immune and inflammatory properties (Demircan et al, 2006). RPE cells 
express chemokine receptors basally (Yamada et al., 2006, Blaauwgeers HG et al., 
1999). It has been recognised that low grade inflammation plays a role in AMD. Thus 
the inflammatory response in AMD lesions is characterised by an infiltration of the 
BRB, including the RPE layer, by both macrophages and lymphocytes (Penfold et al., 
2002, Reddy et al., 1995). 
 
Studies involving AMD eyes were pursued, where the composition of drusen, 
extracellular deposits and plaques that accumulate in close association with the RPE, 
were investigated (Grossniklaus et al., 2005, Anderson DH et al., 2002, Hageman GS 
et al., 2001). The presence of few small drusen in the macula of patients aged over 40 
is not considered harmful; however the increase in size and number of drusen deposits 
contributes to progressive AMD (An E et al, 2008). Drusen has been shown to attract 
macrophages to the sub-RPE space (Lopez PF et al, 1991) and results showed the 
major cellular components in CNV membranes included macrophages and fibroblasts 
(Grossniklaus et al., 2005). It is known that the major inflammatory cytokines 
produced by macrophages, neutrophils and lymphocytes are IFN-gamma, TNF–α and 
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IL1-β (An E et al, 2008), and these cytokines may be produced locally at the RPE. 
Furthermore, TNF-α and IL1-β are linked with pro-inflammatory RPE cell functions 
(Hollborn et al., 2001, Elner VM et al., 1997). TNF–α and IL-1 has been found in 
ocular specimens of autoimmune anterior uveitis (Patel and Chan, 2008) and the 
neovascular membranes of wet AMD (Wan L et al 2010, An E et al, 2008). In this 
work we have studied two pro-inflammatory cytokines, IL1-β, which is produced by 
activated macrophages, and TNF–α, which is produced primarily by macrophages, as 
well as other cell types. 
 
5.2 Tumor necrosis factor alpha (TNF-α) 
Tumor necrosis factors (TNFs) are a family of immuno-modulatory cytokines which 
are produced in response to inflammatory stimuli. TNFs are usually produced by 
activated macrophages and monocytes in the human body. Tumor necrosis factor 
alpha (TNF-α) is a potent pro-inflammatory cytokine with a number of biological 
effects (Holtkamp 2001). It is produced in the body, primarily by monocytes and 
macrophages, and plays a key role in initiation of immune responses in the body. 
 
RPE cells express TNF-α receptors on their apical side (An E et al 2008). However, it 
is unclear whether RPE cells are a source of TNF-α. TNF-α has been implicated in 
pathogenesis of AMD (Dias JR et al 2011, Wan L et al 2010) and Diabetic 
Retinopathy (Joussen AM et al, 2002). TNF-α has been reported to stimulate 
production of VEGF by RPE cells, in pathogenesis of neovascular AMD. Kociok N et 
al., 1998 found no evidence for expression of TNF-α in non-stimulated RPE cells, in 
agreement with Tanihara H et al., (1992). However, it was reported that stimulation of 
RPE cells with IL-1B induce expression of TNF-α mRNA, although the protein was 
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not secreted (Tanihara H et al., 1992). De Kozak et al (1994) described production of 
TNF-α by three different strains of rat RPE cells in a constitutive manner, and this 
secretion of TNF-α correlated to their susceptibility to uveitis. Gustavsson C et al 
(2008) and Limb GA et al (1996) reported elevated levels of serum TNF-α may serve 
as an independent serum marker for development of PDR in type-1 diabetic patients. 
 
5.3 Interleukin -1 beta (IL-1β) 
The Interleukins are a large family of immuno-modulatory cytokines. Some of these 
are produced by RPE cells (Holtkamp et al, 2001). Interleukin-1 (IL-1) is one of the 
most potent mediators of immune response. These responses are either pro-
inflammatory or lead to activation of immune system (Holtkamp et al, 2001). Two 
forms of IL-1 identified are Interleukin – 1 alpha (IL-1α) and Interleukin -1 beta (IL-
1β). IL-1β is a potent pro-inflammatory cytokine which is found in elevated levels in 
patients suffering from proliferative vitreo retinopathy (PVR) and ocular 
inflammation (Demircan et al. 2006, Patel et al. 2006, Liou et al., 2002, Franks et al. 
1992). Unstimulated RPE cells do not express genes for IL-1β or IL-1α, but the gene 
expression is readily induced by external stimuli such as endotoxin or 
lipopolysaccharide (Holtkamp et al, 2001). IL-1 produced by RPE cells play a role in 
inflammatory processes involving the retina (Holtkamp et al, 2001). 
 
RPE cells express multiple receptors for cytokines including the Interleukin-1 
receptor IL-1R (Leung et al 2009). RPE cells when stimulated with TNF – α and IL-
1β, secretes IL-6 and IL-8 which are pro-inflammatory cytokines (Jaffe et al. 1995, 
Elner et al, 1992). IL-6 was found to activate macrophages and T-cells in vitro. 
Elevated levels of IL-6 were found in vitreous of patients suffering from PDR and 
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PVR as compared to a healthy eye (Canataroglu et al. 2005, Kojima et al, 2001). IL-8 
is a pro-angiogenic cytokine and has the ability to activate neutrophils after they 
arrive at the site of infection (Holtkamp et al, 2001). RPE cells secrete IL-6 and IL-8 
basally, towards the choroidal side, in a polarized manner (Holtkamp et al, 1998). 
 
5.4 Aims 
TNF- α and IL-1β have been associated with inflammatory conditions involving RPE 
and has been implicated in the pathogenesis of AMD and DR (Wan L et al, 2010, 
Demircan et al 2006). TNF-α is produced locally at oBRB by macrophages in low 
grade inflammatory conditions related to AMD.  TNF-α may modulate expression of 
RPE tight junctions and disrupt oBRB. Elevated level of IL-1β is found in the vitreous 
of patients suffering from proliferative vitreo retinopathy (PVR) and ocular 
inflammation (Demircan et al. 2006, Patel et al. 2006, Liou et al., 2002, Franks et al. 
1992). IL-1β may affect localization and expression of TJ proteins. Change in 
expression and localization of occludin, Zo-1, β-catenin and claudins were studied 
using western blotting and immunoflourescence staining. Toxicity of cytokines to the 
RPE was investigated using a standard Trypan blue assay. 
 
5.5 Cell culture and cytokine treatment  
ARPE-19 cells were cultured as described in section 2.2.1 until desired confluence 
was achieved. They cell monolayer was then rinsed with sterile PBS and incubated 
with serum free medium for 6 hours followed by treatment with 1ng/ml to 10ng/ml of 
TNF-α or IL-1β for 24 hours in serum free medium. After treatment, the cell 
monolayer was rinsed with sterile PBS to remove any traces of medium. The cells 
were then extracted as described in section 2.2.2. Protein analysis of the cell extract 
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was performed using the Bradford assay. Equal amounts of protein per sample were 
loaded on to minigels. Electrophoresis was performed as described in section 2.2.4. 
The separated proteins were then blotted to a nitrocellulose membrane as described in 
2.2.5. Transfer time used was 2 hours for Occludin, β-catenin and claudins and 3.5 
hours for Zo-1.  
 
5.6 Results and Discussion 
5.6.1 Occludin expression in RPE treated with TNF-α 
RPE cells exposed to various concentrations of TNF-α or IL-1β showed significant 
alterations in expression of specific tight junction proteins investigated in this study. 
Western blot analysis of occludin expression in RPE exposed to TNF-α for 24 hours 
showed a strong down-regulation of the protein (Fig 5.1). Mean occludin band 
intensities showed a statistically significant (P≤0.05) decrease in occludin expression 
when treated with TNF-α (Table 5.1) 
 
 
Fig.5.1 Western blot analysis of RPE cells treated with 0ng/ml, 1ng/ml and 
10ng/ml TNF-α showing down-regulation of occludin. 
The blot was developed using chemiluminescence. Normalisation of blots was 
achieved using beta actin. Blot was performed twice. 
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TNF-α 
concentration Mean P Value 
0ng/ml 8603.5 
1ng/ml 7061 
10ng/ml 1516.5 
0.0144 
 
Table 5.1 Mean band intensities for two sets of samples shows a decrease in occludin 
band intensity with exposure to TNF-α. P-value calculated by single factor ANOVA 
shows that this change is statistically significant (P≤0.05) for 10ng/ml TNF-α treated 
RPE 
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Fig 5.2. Effect of TNF-α treatment on occludin expression in RPE cells. 
Occludin in RPE is down-regulated with exposure to TNF-α. The graph represents the 
mean value for two western blot analyses and the standard error of the mean is 
represented by Y-error bars. 
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5.6.2 Zo-1 expression in RPE cells treated with TNF-α 
Zo-1 is associated with the cytoplasmic domain of occludin and assists in localization 
of occludin on the membrane, in order to form tight junctions (Umeda et al, 2006). 
Change in Zo-1 distribution affects stability of the occludin molecule and may cause 
disruption of the occludin dimer. Zo-1 in RPE is significantly down-regulated by 
TNF-α treatment, as evident from western blot analysis (Fig 5.3).  
 
 
 
Fig.5.3. Western blot analysis of RPE cells treated with 0ng/ml, 1ng/ml and 
10ng/ml TNF-α showing down-regulation of Zo-1. 
The blot was developed using chemiluminescence. Normalisation of blots was 
achieved using beta actin. Blot was performed twice. 
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TNF-α 
concentration Band intensity (Mean ±SEM) P Value 
0ng/ml 8434.3 ± 3564 
1ng/ml 2294.3± 821 
10ng/ml 1997.3 ± 336 
0.129 
 
Table 5.2 - Mean band intensities (± standard error of mean) for three sets of samples 
treated with TNF-α shows a progressive decrease in Zo-1 band intensity with 
exposure to TNF-α. P-value calculated using single factor ANOVA shows that this 
change is not statistically significant (P>0.05) 
Effect of TNF-α on Zo-1 expression in RPE
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Fig 5.4. Effect of TNF-α treatment on Zo-1 expression in RPE cells. 
Zo-1 in RPE is down-regulated with exposure to TNF-α. The graph represents the 
mean value for three western blot analyses and the standard error of the mean is 
represented by Y-error bars. 
 
 
______________________ Effect of Cytokines on the outer Blood Retinal Barrier 
 91 
Cultured RPE cells treated with TNF-α were fixed and then stained for Zo-1 using 
FITC. The staining showed disruption of membrane junctions and loss of Zo-1 when 
treated with 1ng/ml TNF-α (Fig 5.5).  
a) 
 
b) 
  
Fig: 5.5 Immunoflourescence staining showing change in localization of Zo-1 in 
cultured RPE cells treated with TNF-α: Untreated (a) and Treated with 1ng/ml TNF-α 
(b). RPE cells were stained using FITC and images captured at 40x magnification. 
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There are very few studies on TNF-α mediated regulation of tight junction proteins in 
oBRB (Gan et al 2011, Narayan et al 2003). A study of salivary gland epithelia 
exposed to TNF-α and IFNγ in vivo showed down-regulated occludin and Zo-1 
expression and disrupted barrier function in salivary glands (Ewert et al., 2010). 
 
5.6.3 Claudin -2 expression in RPE cells treated with TNF-α 
To investigate whether, TNF-α mediates expression of claudins in RPE, changes in 
selected claudins were studied. Data from western blot showed an increase in claudin-
2 band density in RPE treated with 1ng/ml TNF-α (Fig 5.6). Densitometric analysis of 
claudin-2 bands (Table 5.3) showed that this increase was statistically significant 
(P≤0.05).  
 
Fig.5.6 Western blot analysis of RPE cells treated with 0ng/ml, 1ng/ml and 
10ng/ml TNF-α showing up-regulation of claudin-2. 
The blot was developed using chemiluminescence. Normalisation of blots was 
achieved using beta actin. Blot was performed twice. 
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10ng/ml TNF-α treated RPE show a slight drop in claudin-2 expression (Fig 5.7) 
which could be explained by reduced viability of cells treated with 10ng/ml TNF-α. 
 
TNF-α 
concentration Mean P Value 
0ng/ml 14997 
1ng/ml 28685 
10ng/ml 20066 
0.0376 
Table 5.3: Mean band intensities for two sets of samples shows increase in claudin-2 band 
intensity with exposure to 1ng/ml TNF-α. P-value calculated using single factor ANOVA 
shows that this change is statistically significant (P≤0.05) for TNF-α treated RPE. 
TNF-α upregulates claudin-2 expression in RPE
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Fig 5.7 Effect of TNF-α treatment on claudin-2 expression in RPE cells. 
Claudin-2 in RPE is up-regulated with exposure to TNF-α. The graph represents the mean 
value for two western blot analyses and the standard error of the mean is represented by 
Y-error bars. 
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5.6.4 Claudin – 3 expression in RPE cells treated with TNF-α. 
An increase in expression of claudin-3 in RPE when stimulated with 1ng/ml TNF-α, 
was observed from western blot analysis (Fig 5.8). Mean band density calculated 
showed an increase in claudin-3 expression in 1ng/ml TNF-α treated RPE (Fig 5.9). 
However, statistical analysis of claudin-3 band densities (Table 5.4) showed that this 
change is not significant (P>0.05). The reduction in claudin-3 expression when treated 
with higher concentration of TNF-α may be attributed to the reduced viability of RPE 
cells as observed from trypan blue assay (Fig 5.24) 
 
 
Fig 5.8 Western blot analysis of RPE cells treated with 0ng/ml, 1ng/ml and 
10ng/ml TNF-α showing change in claudin-3 expression. 
The blot was developed using chemiluminescence. Normalisation of blots was 
achieved using beta actin. Blot was performed twice. 
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TNF-α 
concentration Mean P Value 
0ng/ml 16741.5 
1ng/ml 21422 
10ng/ml 16675 
0.621 
 
Table 5.4: Mean band intensities for two sets of samples shows an increase in 
claudin-3 band intensity with exposure to 1ng/ml TNF-α. P-value calculated using 
single factor ANOVA shows that this change is not statistically significant for TNF-α 
treated RPE 
Effect of TNF-α on Claudin-3 expression in RPE
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Fig 5.9 Effect of TNF-α treatment on claudin-3 expression in RPE cells. 
Claudin-3 expression in RPE is higher with exposure to 1ng/ml TNF-α. The graph 
represents the mean value for two western blot analyses and the standard error of the 
mean is represented by Y-error bars 
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5.6.5 Claudin – 4 expression in RPE cells treated with TNF-α. 
TNF-α treated RPE cells showed up-regulation of claudin-4, as indicated by western 
blotting data (Fig 5.10). Densitometric analysis showed that this effect was not 
statistically significant (P>0.05) for TNF-α treated RPE. The reduction in claudin-4 
expression when treated with higher concentration of TNF-α may be attributed to the 
reduced viability of RPE cells as observed from trypan blue assay (Fig 5.24) 
 
Fig 5.10 Western blot analysis of RPE cells treated with 0ng/ml, 1ng/ml and 
10ng/ml TNF-α showing up-regulation of claudin-4. 
The blot was developed using chemiluminescence. Normalisation of blots was 
achieved using beta actin. Blot was performed thrice. 
 
Density analysis shows a slight up-regulation of claudin-4 in RPE treated with 1ng/ml 
TNF-α (Table 5.5), although not statistically significant. A similar study on salivary 
epithelium (Ewert et al, 2010) shows a strong increase in expression of claudin-4 in 
epithelial cells exposed to pro-inflammatory cytokines TNF-α and IFNγ while down-
regulating occludin and Zo-1 expression. 
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TNF-α 
concentration 
Band intensity (Mean 
±SEM) 
P 
Value 
0ng/ml 3467.67 ± 595 
1ng/ml 6232.67 ± 222 
10ng/ml 6047 ± 1111 
0.0673 
 
Table 5.5: Mean band intensities (± standard error of mean) for three sets of samples 
treated with TNF-α shows an increase in claudin-4 band intensity with exposure to 
TNF-α. P-value calculated using single factor ANOVA shows that this change is not 
statistically significant for TNF-α treated samples. 
Effect of TNF-α on claudin-4 expression in RPE
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Fig 5.11 Effect of TNF-α treatment on claudin-4 expression in RPE cells. 
Claudin-4 in RPE is up-regulated with exposure to TNF-α. The graph represents the 
mean value for three western blot analyses and the standard error of the mean is 
represented by Y-error bars. 
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5.6.6 Beta-catenin expression in RPE cells treated with TNF-α. 
Beta catenin expression change indicates change in adherens junctions located basally 
in the RPE layer. Protein blot analysis indicated a decrease in beta catenin expression 
in RPE treated with TNF-α, against untreated RPE (Fig 5.12, Fig 5.13). Statistical 
analysis of band intensities, however, showed that this is not statistically significant 
(Table 5.6).  
 
 
 
Fig 5.12 Western blot analysis of RPE cells treated with 0ng/ml, 1ng/ml and 
10ng/ml TNF-α showing down-regulation of beta-catenin 
The blot was developed using chemiluminescence. Normalisation of blots was 
achieved using beta actin. Blot was performed thrice. 
 
Investigation of change in beta-catenin localization using immunoflourescence did not 
show a noticeable change (Fig 5.14). Overall, the data obtained from these results is 
as yet inconclusive and further studies are warranted. 
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TNF-α 
concentration Band intensity (Mean ±SEM) P Value 
0ng/ml 19131.67 ± 5516 
1ng/ml 16432.33 ± 3106 
10ng/ml 9842.68 ± 3348 
0.331 
 
Table 5.6: Mean band intensities (± standard error of mean) for three sets of samples 
treated with TNF-α shows decrease in beta-catenin band intensity with exposure to 
TNF-α. P-value calculated using single factor ANOVA shows that this change is not 
statistically significant (P>0.05). 
Effect of TNF-α on Beta-catenin expression in RPE
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Fig 5.13 Effect of TNF-α treatment on beta-catenin expression in RPE cells. 
Beta-catenin expression in RPE is down-regulated with exposure to TNF-α. The 
graph represents the mean value for three western blot analyses and the standard error 
of the mean is represented by Y-error bars 
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a) 
 
b) 
  
Fig: 5.14 Immunoflourescence staining showing change in localization of β-catenin in 
cultured RPE cells exposed to 0ng/ml (a) and 1ng/ml (b) TNF-α. RPE cells were stained 
using FITC and nuclei stained using DAPI. Magnification used: 40x. 
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5.6.7 Occludin expression in RPE cells treated with IL-1β 
Western blot analysis of RPE cells treated with IL-1β showed a positive increase in 
expression of occludin (Fig 5.14). Mean values (± standard error of mean) were 
calculated from band density analysis of three sets of data (Table 5.7). The mean band 
intensities show a progressive increase in occludin expression with increasing 
concentrations of IL-1β (Fig 5.15). Statistical analysis of data obtained showed that 
this change is significant for 10ng/ml IL-1β treated sample. 
 
 
 
Fig.5.14. Western blot result analysis of RPE cells treated with 0, 1 and 10ng/ml 
of IL-1β.  
Blot was developed using chromogenic substrate – BCIP / NBT. Normalisation of 
blots was achieved using beta actin. Blot was performed thrice. 
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IL-1β 
concentration Band intensity (Mean ±SEM) P Value 
0ng/ml 1698 ± 454 
1ng/ml 3519.3 ± 680 
10ng/ml 5006.3 ± 575 
0.019 
 
 Table 5.7 Mean band intensities (± standard error of mean) for three sets of samples 
treated with IL-1β shows increase in occludin band intensity with exposure to IL-1β. 
P-value calculated using single factor ANOVA shows that this change is statistically 
significant (P≤0.05). 
IL-1β upregulates Occludin expression in RPE
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Fig 5.15 Effect of IL-1β treatment on occludin expression in RPE cells. 
Occludin expression in RPE is up-regulated with exposure to IL-1β. The graph 
represents the mean value for three western blot analyses and the standard error of the 
mean is represented by Y-error bars 
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Immunoflourescence data showed change in occludin localization in RPE cells treated 
with IL-1β (Fig 5.16) although IL-1β treated RPE shows occludin upregulation (Table 
5.7). Further studies are recommended to understand whether the folding pattern of 
occludin is affected by IL-1β affecting it’s localisation at tight junctions. 
a)  
b)  
Fig 5.16 Immunoflourescence staining showing change in localization of occludin in 
cultured RPE cells treated with IL-1β: Untreated (a) and Treated with 10ng/ml IL-1β 
(b). RPE cells were stained using FITC and images captured at 40x magnification. 
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5.6.8 Zo-1 expression in RPE cells treated with IL-1β 
RPE exposed to IL-1β showed clear loss of Zo-1, as indicated by western blot 
analysis (Fig 5.17). Mean values calculated from band density analysis of two sets of 
data (Table 5.8) showed that this change was statistically significant for 10ng/ml IL-
1β treated RPE. Analysis of mean band density values of two blots showed 
progressive down-regulation of Zo-1 with increase in concentration of IL-1β (Fig 
5.18) 
 
 
Fig 5.17 Western blot analysis of RPE cells treated with 0ng/ml, 1ng/ml and 
10ng/ml IL-1β showing down-regulation of Zo-1. 
The blot was developed using BCIP/NBT substrate. Normalisation of blots was 
achieved using beta actin. Experiment was performed twice. 
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IL-1β 
concentration Mean P Value 
0ng/ml 7457 
1ng/ml 4992.5 
10ng/ml 1794 
0.037 
Table 5.8: Mean band intensities for two sets of samples treated with IL-1β shows a 
decrease in Zo-1 band intensity with exposure to IL-1β. P-value calculated using single 
factor ANOVA shows that this change is statistically significant (P≤0.05) for IL-1β 
treated RPE. 
IL-1β downregulates Zo-1 expression in RPE
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Fig 5.18 Effect of IL-1β treatment on Zo-1 expression in RPE cells. 
Zo-1 is significantly down-regulated with exposure to IL-1β. The graph represents the 
mean value for two sets of data. The standard error of the mean is represented by Y-error 
bars. 
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A decrease in Zo-1 as observed from western blotting suggested that membrane 
localization of Zo proteins may be affected. Immunoflourescence staining of 10ng/ml 
IL-1β treated RPE showed loss of Zo-1 from membrane junctions (Fig 5.19). 
a)  
b)  
Fig: 5.19 Immunoflourescence staining showing junctional loss of Zo-1 in cultured RPE 
cells exposed to different concentrations of IL-1β: Untreated (a) and Treated with 10ng/ml 
IL-1β (b). RPE cells were stained using FITC and images captured at 40x magnification. 
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5.6.9 Claudin – 1 expression in RPE cells treated with IL-1β 
Claudins associate in a heteromeric manner to form tight junctions (Furuse, 2010). An 
increase in claudin-1 expression was shown by western blotting data (Fig 5.20). Mean 
band density values showed that this change was statistically significant for 10ng/ml 
IL-1β treated RPE (Table 5.9). Claudin-1 was progressively up-regulated with 
exposure to increased concentrations of IL-1β (Fig 5.21). 
 
 
Fig 5.20: Western blot analysis of RPE cells treated with 0ng/ml, 1ng/ml and 
10ng/ml IL-1β showing up-regulation of claudin-1. 
The blot was developed using chemiluminescence substrate. Normalisation of blots 
was achieved using beta actin. Experiment was performed twice. 
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TNF-α 
concentration Mean P Value 
0ng/ml 1016.5 
1ng/ml 2219 
10ng/ml 5489.5 
0.033 
 
Table 5.9 Mean band intensities for two sets of samples shows an increase in claudin-
1 band intensity with exposure to IL-1β. P-value calculated using single factor 
ANOVA shows that this change is statistically significant (P≤0.05) for IL-1β treated 
RPE 
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Fig 5.21 Effect of IL-1β treatment on claudin-1 expression in RPE. 
Claudin-1 expression shows progressive increase in RPE cells treated with increasing 
concentrations of IL-1β. The graph represents the mean value for two sets of data.  
The standard error of the mean is represented by Y-error bars. 
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5.6.10 Claudin – 3 expression in RPE cells treated with IL-1β 
 
 
Data obtained from western blotting showed an increase in claudin-3 with IL-1β 
treatment (Fig 5.22). Statistical analysis of three sets of data (Table 5.10) showed that 
this change was not statistically significant.  
 
 
 
Fig 5.22 Western blot analysis of RPE cells treated with 0ng/ml, 1ng/ml and 
10ng/ml IL-1β showing up-regulation of claudin-3. 
The blot was developed using chemiluminescence substrate. Normalisation of blots 
was achieved using beta actin. Experiment was performed thrice. 
 
 
 
 
 
 
0ng/ml 1ng/ml 10ng/ml 
Beta-actin 
Claudin - 3 
50 
 
40 
30 
 
 
20 
______________________ Effect of Cytokines on the outer Blood Retinal Barrier 
 110 
IL-1β 
concentration Band intensity (Mean ±SEM) P Value 
0ng/ml 2382.3 ± 803.87 
1ng/ml 3798.3 ± 328.75 
10ng/ml 1435.7 ± 1490.5 
0.070 
 
Table 5.10 Mean band intensities (± standard error of mean) for three sets of samples 
treated with IL-1β shows increase in claudin-3 band intensity with exposure to 1ng/ml 
IL-1β. P-value calculated using single factor ANOVA shows that this change is not 
statistically significant (P>0.05). 
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Fig 5.23 Effect of IL-1β treated RPE cells on claudin-3 expression. 
Claudin-3 expression in RPE is increased with exposure to 1ng/ml IL-1β. The graph 
represents mean values for triplicate determinations. The standard error of the mean is 
represented by Y-error bars. 
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5.7 Viability assay 
RPE cells were treated with 1ng/ml and 10ng/ml TNFα and 1ng/ml and 10ng/ml IL-
1β as described in section 2.2.2. Cell viability assay was performed as per protocol 
outlined in section 2.2.6. 
a) TNFα 
Cell viability for samples treated with 1ng/ml and 10ng/ml TNF-α were found to be 
about 95% (57 viable out of 60cells) and 92% (40 viable out of 45cells) respectively, 
after exposure to trypan blue for 5 minutes. 
b) IL-1β 
Cells exposed to 1ng/ml and 10ng/ml IL-1β for 24 hours showed 99% (99 viable out 
of 100 cells) and 97% (68 viable out of 70 cells) viability respectively, after exposure 
to trypan blue for 5 minutes. 
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Fig: 5.24 - Graph showing percentage viability of cells treated with 1ng/ml and 
10ng/ml of TNFα / IL-1β for 24 hours. 
Both cytokines are released as a part of inflammatory response produced during later 
stages of non-neovascular ARMD (Nagineni et al, 2011). TNF-α and IL-1β are not 
secreted by unstimulated RPE cells (Holtkamp et al. 2001). Differential levels of 
TNF-α and IL-1β were found in vitreous in various studies. However, it was generally 
demonstrated that vitreous levels of TNF-α and IL-1β are elevated in PVR and PDR 
(Kojima et al, 2001) and the difference in result may be attributed to leakage of 
cytokines through a disrupted oBRB into systemic circulation through a disrupted 
BRB as suggested by Demircan et al, (2006) 
 
A decrease in Zo-1 expression suggests that membrane localization of Zo proteins 
may be affected. This suggests possible disruption of the membrane barrier in 
response to increased exposure to IL-1β and TNF-α. Immunoflourescence images of 
RPE cells exposed to 10ng/ml IL-1β (Fig 5.17) shows nearly complete loss of Zo-1. 
Also, RPE cells exposed to 1ng/ml and 10ng/ml TNF-α shows 5% and 8% loss in 
viability respectively (Fig 5.24). The data obtained suggests that IL-1β and TNF-a 
may play a role in breakdown of outer BRB in ARMD, leading to photoreceptor 
damage and vision loss. 
 
We found a considerable down-regulation of β-catenin in RPE exposed to TNF-α (Fig 
5.13). This may indicate a disruption of adherens junctions in RPE with exposure to 
TNF-α in pathological conditions. β-catenin associates with cadherins cytoplasmically 
and plays a role in connecting them to F-actin. However, E-cadherin expression was 
not detected in cultured ARPE-19 cells using western blot (data not shown). 
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Data obtained from western blotting shows that IL-1β up-regulates occludin 
expression in RPE (Fig 5.15) over 24 hours. This contradicts results obtained by Abe 
T et al (2003) where occludin expression was down-regulated with exposure to 
10ng/ml IL-1β. This could be explained by the difference in experimental conditions 
provided in both studies. Abe T et al. (2003) do not state whether RPE was exposed to 
IL-1β in a serum free environment. Serum contains other cytokines which may 
interfere with or mask the effects of IL-1β. RPE cells treated with 1ng/ml IL-1β 
shows up-regulated claudin – 1 expression (Fig 5.21). This is in agreement with the 
study conducted by Abe T et al (2003). Moreover, in their study, claudin-1 and 
occludin expression was measured over a much longer period of time as opposed to 
the 24 hour period used in this study. Our immunoflourescence results show abnormal 
occludin distribution, with discontinuous, diffuse staining for occludin, for IL-1β 
treated RPE (Fig 5.16). IL-1β is shown to differentially regulate occludin expression 
in other tissues. IL-1β down-regulates occludin expression in human foetal astrocytes 
(Duffy HS et al, 2000), but does not influence the occludin expression in HaCaT 
keratinocyte cells (Rozlomiy and Markov, 2010). 
 
Claudin-3 was up-regulated in RPE treated with 1ng/ml IL-1β (Fig 5.22). Claudin-3 
forms heterotypic tight junctions in epithelia by binding to claudin-1 or claudin-2 
(Furuse 2010, Milatz et al, 2010, Turksen and Troy 2004). Increase in claudin-3 and 
claudin-4 expression may be in parallel with that of claudin-2 (Fig 5.7) or claudin-1 
(Fig 5.19) expression in cytokine stimulated RPE. Transfection of MDCK-II kidney 
tubule cells with claudin-3 caused in increase in TEER (Milatz S et al, 2010) but 
brings no change in MDCK-I cells (Turksen and Troy, 2004). The functions of 
______________________ Effect of Cytokines on the outer Blood Retinal Barrier 
 114 
claudin-3 are not fully elucidated. Hence further studies are required to understand 
this behaviour of claudin-3 
 
Viability data obtained using Trypan blue assay (Fig 5.24) shows progressive 
decrease in viability of RPE cells with increased concentration of cytokines added. 
This may explain the slight drop in expression of claudins which were over-expressed 
when exposed to 1ng/ml TNF-α or IL-1β. 
 
Overall, our data indicates that pro-inflammatory cytokines TNF-α and IL-1β may 
have a regulatory effect on RPE barrier in pathological conditions. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 6 
 
Discussion 
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The most recent WHO factsheet on blindness reports that about 285 million people 
worldwide are visually impaired. Of these, 65% are aged 50years and up. AMD has 
been listed as one of the major causes of vision loss in the west. Breakdown of the 
blood retinal barrier is the hallmark of AMD, which leads to severe retinal damage 
and vision loss. The exact molecular mechanism which leads to disruption of this 
BRB tissue has not been fully elucidated. The pathology and progression of AMD is 
also not fully understood. 
 
Studies on the RPE tissue which lines the outer layer of retina showed that it plays a 
significant role in maintenance of the retinal integrity. The RPE was also shown to 
secrete several cytokines and growth factors to the surrounding medium under 
pathological conditions such as hypoxia. VEGF, PlGF, TNF-α and IL-1β are found at 
elevated levels in vitreous of patients suffering from AMD.  
 
Experimental conditions employed in this study involved stimulation of cultured 
ARPE-19 cells with various concentrations of growth factors or cytokines for 24 
hours. Protein expression analysis of E-cadherin in RPE cells showed no signal for E-
cadherin in cultured ARPE-19 cells (data not shown). Cultured brain endothelial cells 
(Endo BalbC) were used as a positive control. Earlier studies show that though human 
RPE cells express E-cadherin in vivo, this decrease in vitro with progressive cell 
culture passages (Burke and Hong, 2006). 
 
6.1 Effect of VEGF on oBRB 
Studies conducted by Brankin et al (2005) showed that VEGF165 had a synergistic 
effect on inner BRB permeability both in vivo and in vitro. VEGF significantly 
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increased BRMEC paracellular permeability and induced iBRB breakdown. Increased 
vitreal VEGF levels were found in AMD patients. Progressive stages of AMD are 
known to cause choroidal neovascularisation as a result of hypoxia induced VEGF 
secretion. VEGF treatment of RPE layer in vitro did not indicate any significant 
change in the overall occludin content at first glance, when probed using western 
blotting. Fluorescence microscopy showed change in localization of occludin from 
membrane in VEGF treated RPE cells. Zo-1 associates with the cytoplasmic terminal 
of occludin and is responsible for stabilization of occludin and claudins in tight 
junctions (Fanning et al. 1998). Earlier studies on retinal endothelial cells have shown 
a significant increase in Zo-1 expression with in vitro VEGF treatment (Ghassemifar 
et al. 2006, Brankin and Stitt 2003). Other researchers in the lab have found that 
VEGF also caused an increase in expression of Zo-1 protein and mRNA levels for 
RPE (by personal communication with Dr. Brenda Brankin).  
 
There is evidence that VEGF induces phosphorylation of Zo-1 in vitro (Bates, 2010) 
and indirectly contributes to phosphorylation of occludin (Harhaj et al 2006).  
However, relatively little published data is available regarding how this may be 
significant in VEGF induced breakdown of the RPE barrier. Further studies are 
required to investigate whether VEGF induced phosphorylation of Zo-1 attenuates 
interaction with occludin, leading to membrane de-localization of occludin. A FITC 
dextran permeability assay and changes in trans-epithelial electrical resistance 
(TEER) would provide conclusive evidence on whether RPE barrier permeability is 
altered by VEGF treatment. 
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6.2 Effect of PlGF on oBRB  
PlGF is actively secreted by RPE cells subjected to hypoxic conditions (Hollborn et 
al, 2006). PlGF is a member of VEGF family and has been reported to potentiate the 
activity of VEGF (Hollborn et al 2006). PlGF reportedly induced phosphorylation of 
occludin at serine and threonine residues, which may modify its capacity to associate 
with Zo-1 cytoplasmically (Brankin and Stitt, 2003). Investigation of change in 
polarity of RPE cells would provide more conclusive evidence on this. Little 
information is available on the effect of PlGF on permeability of the RPE barrier 
(Carmeliet P et al, 2001).  
 
Elevated PlGF of upto 1ng/ml was found in vitreous of diabetic patients (Mitamura et 
al 2002). The effect of PlGF on occludin expression in RPE is not yet fully confirmed 
(Kowalczuk et al., 2011, Ablonczy and Crosson 2007, Mitamura et al. 2002). Our 
data did not show any significant change in RPE occludin content with PlGF 
treatment. Hollborn et al (2006) suggested that PlGF may have an autocrine or 
paracrine effect on RPE cells. Further investigation into change in permeability and 
polarity of RPE is required to obtain better insight in this matter. A synergistic 
increase in VEGF along with PlGF was observed by Hollborn M et al (2006). It was 
suggested that PlGF may stimulate secretion of VEGF by RPE cells in pathological 
conditions (Dull et al. 2001, Park et al, 1994). 
 
6.3 Effect of TNF-α and IL-1β on oBRB 
RPE cells are continuously exposed to oxidative stress and pro-inflammatory stimuli 
(Strauss, 2005). The pro-inflammatory cytokines, IL-1β and TNF-α, are released by 
macrophages during inflammation associated with several ocular dystrophies. 
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Differential levels of TNF-α and IL-1β were found in vitreous in various studies. 
However, it was generally demonstrated that vitreous and serum levels of TNF-α and 
IL-1β are elevated in PVR and PDR (Demircan et al, 2006, Kojima et al, 2001) and 
the presence of vitreous haemorrhage and oBRB breakdown may lead to leakage of 
cytokines into the systemic circulation (Demircan et al, 2006) 
 
Cytokine gene expression is readily induced in RPE cells by inflammatory stimuli 
(Holtkamp et al, 2001) and hence RPE cells may act as a source of IL-1β and TNF-α 
in AMD pathogenesis. Vitreous levels of IL-1β were found to be elevated in 
progressive DR (Patel et al, 2008(a), Demircan et al 2006). Differential 
concentrations of IL-1β and TNF-α were obtained in different studies involving 
retinal inflammation (Gustavsson et al., 2008, Demircan et al., 2006, Kauffmann et 
al., 1994). It was hence suggested that both serum and vitreous concentrations of 
cytokines IL-1β and TNF-α must be taken into account, as vitreous haemorrhage and 
oBRB breakdown leads to leakage of IL-1β and TNF-α into the systemic circulation. 
Results suggested simultaneous production of IL-1β and TNF-α from the RPE and 
macrophages (Demircan et al, 2006). 
 
TNF-α is secreted locally by macrophages infiltrating into the outer retina under 
pathologic conditions. Stimulated RPE cells secrete IL-1β basally in a polarized 
manner (Holtkamp et al., 2001). RPE shows immunoreactivity to both cytokines (Oh 
et al, 1999, Jaffe et al, 1992). Increased concentration of TNF-α in surrounding 
medium is toxic to RPE cells and caused occludin loss from RPE. Loss of both tight 
junction and adherens junctions indicate possible change in polarity of RPE cells. 
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RPE exposed to TNF-α showed an increase in claudin-2 expression. Claudin–2 was 
up-regulated significantly when treated with 1ng/ml TNF-α. This result was in 
agreement with studies involving TNF-α-induced change in Claudin-2 in intestine and 
RPE (Gan et al. 2011, Yu 2009, Mazzon and Cuzzorea, 2008). A cationic pore 
function of Claudin-2 has been suggested (Gupta and Ryan 2010, Lal-Nag and Morin 
2009, Zeissig et al 2007). An increase in Claudin-2 expression possibly indicates an 
increase in ion channel permeability of RPE cells. A similar increase in expression of 
claudin-2 has been reported in colon stimulated with TNF-α (Weber et al. 2010, 
Hering and Schulzke 2009). An over-expression of claudin-2 has been reported to 
reduce TEER and increase paracellular water flux (Rosenthal et al., 2010). 
 
Increase in occludin expression has been shown to enhance baseline barrier properties 
of epithelia (Van Itallie et al, 2010). It is possible that cytokines increase the 
permeability of the RPE barrier to both charged and non-charged solutes by up-
regulating the pore proteins, while down-regulating proteins that restrict paracellular 
permeability. This has to be further confirmed using a permeability assay. 
 
Claudin-4 expression in non-retinal tissues is stimulated by exposure to TNF-α (Ewert 
et al, 2010, Gupta and Ryan 2010). Claudin-3 and 4 are reportedly up-regulated in 
several carcinomas in conjunction with increased TNF-α expression (Gupta and Ryan, 
2010, Yuan et al 2009). However, their role in the retinal barrier modulation is poorly 
investigated. 
 
There was a clear loss of Zo-1 and the band intensity of 10ng/ml IL-1β-treated 
samples was significantly lower than that of control. Zo proteins have a pivotal role in 
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binding occludin and claudins to the actin cytoskeleton and stabilizing the tight 
junctions. Even though occludin expression in RPE was upregulated by IL-1β 
treatment, loss of Zo-1 may cause destabilization of occludin molecules in RPE, 
resulting in the granular staining of occludin observed in IL-1β treated cells. Further 
studies are warranted to understand whether IL-1β causes direct loss of occludin from 
RPE; and to identify whether the loss of Zo-1 affects the polarity of the RPE cells. 
Overall, study indicates that TNF- α and IL-1β may play a regulatory role in blood 
ocular barrier function and in development of ocular inflammation. 
 
In a study similar to the one presented in this thesis, Abe et al (2003) found that 
claudin-1 expression was reduced in RPE cells treated with 10ng/ml IL-1β. Our data, 
on the contrary, shows a significant upregulation of claudin-1 in IL-1β treated RPE. 
Even though this seems to contradict to the data discussed in this thesis; the 
experimental conditions employed by Abe et al., were different, and the claudin-1 
expression was measured after a much longer period, rather than 24 hours employed 
in our experiment. Rozlomiy and Markov (2010) demonstrated that treatment of 
human keratinocyte (HaCaT) cells with IL-1β up-regulated claudin-1 as part of the 
wound healing process. Our data shows that TNF- α and IL-1β may play a regulatory 
role in blood ocular barrier function and in development of ocular inflammation.  
 
Immunoflourescence was not carried out for claudins, as the claudins could not be 
detected in initial staining. Claudin family of proteins have been observed to have a 
host of other functions other than being a structural component of tight junctions. In 
order to get better insight to the significance of the results presented, further roles of 
claudins in RPE need to be identified. Downregulation of claudin using siRNA 
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interference is recommended as a future approach to elucidate the role of specific 
claudin in RPE. Further studies of the effects of cytokines on claudins 2, 3 and 4 in 
RPE are also indicated. 
 
Inflammation plays an important role in pathogenesis and progression of ARMD. 
There is evidence of increased TNF-α secretion in exudative ARMD (Nagineni et al, 
2011). Activation of the RPE with TNF- α or IL-1β results in secretion of RANTES, 
MCP-1 and interleukin 6 and interleukin 8, which affect oBRB function (Crane et al, 
2000).  
 
TNF antagonists have become recognized over the past decade as a key controller of 
inflammatory conditions. Anti-TNF-α therapy has been found to be helpful in 
controlling ARMD-related inflammation and stabilizing vascular angiogenesis 
(Missotten et al., 2007). The role of IL-1β in ocular inflammation is not completely 
elucidated. IL-1β does not directly modulate barrier properties in the tissue. It 
stimulates secretion of other pro-inflammatory chemokines such as IL-6, IL-8 and 
RANTES (Crane et al. 2000). It has been suggested that expression of endogenous 
interleukin-1 receptor antagonist (Jaffe et al 1992) may help in maintaining 
interleukin homeostasis in ocular inflammatory disease. 
 
6.4 Conclusion 
VEGF, PlGF, TNF-α and IL-1β play an important role in modulation of barrier 
properties of oBRB. Differential regulation of oBRB by the selected cytokines and 
growth factors may be helpful in further research on control of inflammation and 
pathological breakdown of oBRB in AMD and PDR. 
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6.5 Future Work 
• VEGF and PlGF treatment of RPE did not yield conclusive results on change 
in permeability of RPE layer. Analysis of permeability change of RPE to 
determine opening of tight junctions, using Flourescein Dextran assay and 
changes in TEER measurement. 
 
• Determination of effects of apical versus basolateral administration of PlGF 
and VEGF on RPE monolayer. 
 
 
• Change in Zo-1 expression and loss of occludin may affect polarity of RPE 
cells in the oBRB. Analysis of change in polarity of RPE cells with growth 
factor and cytokine treatment using Na+ K+ ATPase assay 
 
• The functions of claudins in RPE are not merely structural. Downregulation of 
claudins in RPE using siRNA interference to study the role of individual 
claudins in RPE. 
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